| Year |
Citation |
Score |
| 2024 |
Roy S, Sun Y, Chi KN, Ong M, Malone S, Wallis CJD, Kishan AU, Malone J, Swami U, Gebrael G, Brown JR, Jia AY, Morgan SC, Saad F, Chowdhury S, et al. Early PSA Response by 6 Months is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of TITAN Trial. The Journal of Urology. 101097JU000000000000. PMID 39058790 DOI: 10.1097/JU.0000000000004158 |
0.454 |
|
| 2024 |
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. The TALAPRO-3 study design: a plain language summary. Future Oncology (London, England). 1-7. PMID 39045623 DOI: 10.1080/14796694.2024.2363131 |
0.399 |
|
| 2024 |
Parker CC, Clarke NW, Cook AD, Kynaston H, Catton CN, Cross WR, Petersen PM, Persad RA, Saad F, Bower LC, Logue J, Payne H, Forcat S, Goldstein C, Murphy C, et al. Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial. Lancet (London, England). PMID 38763154 DOI: 10.1016/S0140-6736(24)00548-8 |
0.47 |
|
| 2024 |
Parker CC, Kynaston H, Cook AD, Clarke NW, Catton CN, Cross WR, Petersen PM, Persad RA, Pugh CA, Saad F, Logue J, Payne H, Bower LC, Brawley C, Rauchenberger M, et al. Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial. Lancet (London, England). PMID 38763153 DOI: 10.1016/S0140-6736(24)00549-X |
0.472 |
|
| 2024 |
Hussain M, Fizazi K, Shore ND, Heidegger I, Smith MR, Tombal B, Saad F. Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes: A Review. Jama Oncology. PMID 38722620 DOI: 10.1001/jamaoncol.2024.0591 |
0.491 |
|
| 2024 |
Scheipner L, Baudo A, Jannello LMI, Siech C, de Angelis M, Tian Z, Saad F, Shariat SF, Briganti A, Chun FKH, Carmignani L, De Cobelli O, Mischinger J, Ahyai S, Karakiewicz PI. Contemporary validation of cT1a vs. cT1b substaging of incidental prostate cancer. World Journal of Urology. 42: 269. PMID 38679642 DOI: 10.1007/s00345-024-04940-3 |
0.5 |
|
| 2024 |
Saad F, Hussain MHA, Tombal B, Fizazi K, Sternberg CN, Crawford ED, Nordquist LT, Bögemann M, Tutrone R, Shore ND, Belkoff L, Fralich T, Jhaveri J, Srinivasan S, Li R, et al. Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study. European Urology. PMID 38644146 DOI: 10.1016/j.eururo.2024.03.036 |
0.461 |
|
| 2024 |
Wissing M, Brimo F, McKercher G, Scarlata E, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, Chevalier S, Aprikian A. Long term evaluation of optimized Gleason grading in a large cohort of men with prostate cancer in Canada. Human Pathology. 146: 66-74. PMID 38608782 DOI: 10.1016/j.humpath.2024.04.002 |
0.445 |
|
| 2024 |
Saad F, Armstrong AJ, Oya M, Vianna K, Özgüroğlu M, Gedye C, Buchschacher GL, Lee JY, Emmenegger U, Navratil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Kim J, et al. Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial. European Urology Oncology. PMID 38582650 DOI: 10.1016/j.euo.2024.03.006 |
0.476 |
|
| 2024 |
Roy S, Fervaha G, Spratt DE, Sun Y, Kishan AU, Loblaw A, Malone S, Ong M, Saad F, Wallis CJD, Morgan SC. Prostate Radiotherapy in Low-volume Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. European Urology. PMID 38570246 DOI: 10.1016/j.eururo.2024.03.018 |
0.482 |
|
| 2024 |
Chi KN, Yip SM, Bauman G, Probst S, Emmenegger U, Kollmannsberger CK, Martineau P, Niazi T, Pouliot F, Rendon R, Hotte SJ, Laidley DT, Saad F. Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice. Current Oncology (Toronto, Ont.). 31: 1400-1415. PMID 38534939 DOI: 10.3390/curroncol31030106 |
0.503 |
|
| 2024 |
Phillips WJ, Saad F, Leigh J, Jooya A, Webber C, Morgan S, MacRae R, Bourque JM, Tanuseputro P, Ong M. Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer. The Oncologist. PMID 38527096 DOI: 10.1093/oncolo/oyae036 |
0.552 |
|
| 2024 |
Di Bello F, Baudo A, de Angelis M, Jannello LMI, Siech C, Tian Z, Goyal JA, Collà Ruvolo C, Califano G, La Rocca R, Morra S, Acquati P, Saad F, Shariat SF, Carmignani L, et al. Other-cause mortality in incidental prostate cancer. The Prostate. PMID 38506561 DOI: 10.1002/pros.24689 |
0.469 |
|
| 2024 |
Weber M, Fendler WP, Ravi Kumar AS, Calais J, Czernin J, Ilhan H, Saad F, Kretschmer A, Hekimsoy T, Brookman-May SD, Mundle SD, Small EJ, Smith MR, Perez PM, Hope TA, et al. Prostate-specific Membrane Antigen Positron Emission Tomography-detected Disease Extent and Overall Survival of Patients with High-risk Nonmetastatic Castration-resistant Prostate Cancer: An International Multicenter Retrospective Study. European Urology. PMID 38490855 DOI: 10.1016/j.eururo.2024.01.019 |
0.406 |
|
| 2024 |
Roy S, Saad F, Malone S, Agarwal N, Mohamad O, Morgan SC, Malone J, Swami U, Jia AY, Gebrael G, Mendiratta P, Brown JR, Rao SK, Sun Y, Wallis CJD, et al. Effect of Prior Prostate Directed Local Therapy on Response to Apalutamide in Metastatic Hormone Sensitive Prostate Cancer: A Secondary Analysis of the TITAN Study. European Urology. 85: 398-400. PMID 38485300 DOI: 10.1016/j.eururo.2024.01.003 |
0.487 |
|
| 2024 |
Incesu RB, Morra S, Scheipner L, Barletta F, Baudo A, Garcia CC, Tappero S, Piccinelli ML, Tian Z, Saad F, Shariat SF, de Cobelli O, Terrone C, Chun FKH, Carmignani L, et al. A population-based validation of the IGCCCG Update Consortium for survival in metastatic non-seminoma testis cancer. Japanese Journal of Clinical Oncology. PMID 38369557 DOI: 10.1093/jjco/hyae011 |
0.32 |
|
| 2024 |
Higano CS, Dizdarevic S, Logue J, Richardson T, George S, de Jong I, Tomaszewski JJ, Saad F, Miller K, Meltzer J, Sandström P, Verholen F, Tombal B, Sartor O. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE). Cancer. PMID 38340349 DOI: 10.1002/cncr.35221 |
0.477 |
|
| 2023 |
Saad F, Hotte SJ, Noonan K, Malone S, Morash C, Niazi T, Rendon RA, Shayegan B, Basappa NS, Cagiannos I, Danielson B, Delouya G, Fernandes R, Ferrario C, Finelli A, et al. Addressing controversial areas in the management of advanced prostate cancer in Canada: Areas of consensus and controversy from the third Canadian consensus forum. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 38381937 DOI: 10.5489/cuaj.8537 |
0.424 |
|
| 2023 |
Freedland SJ, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Tutrone RF, Venugopal B, Woo HH, Ramirez-Backhaus M, Supiot S, Lantz A, Ganguli A, Ivanova J, Kral P, Huang SP, ... Saad F, et al. Enzalutamide and Quality of Life in Biochemically Recurrent Prostate Cancer. Nejm Evidence. 2: EVIDoa2300251. PMID 38320501 DOI: 10.1056/EVIDoa2300251 |
0.399 |
|
| 2023 |
Roy S, Saad F, Wallis CJD, Sun Y, Spratt DE, Akilla R, Kishan AU, Malone S, Morgan SC. Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study. European Journal of Cancer (Oxford, England : 1990). 113348. PMID 38262848 DOI: 10.1016/j.ejca.2023.113348 |
0.456 |
|
| 2023 |
Benadada F, Saad F, Delouya G, Taussky D. Charles Brenton Huggins: A historical review of the Nobel laureate's pioneering discoveries. Cancer. PMID 38146679 DOI: 10.1002/cncr.35173 |
0.492 |
|
| 2023 |
Tutrone R, Saad F, George DJ, Tombal B, Bailen JL, Cookson MS, Saltzstein DR, Hanson S, Brown B, Lu S, Fallick M, Shore ND. Testosterone Recovery for Relugolix Versus Leuprolide in Men with Advanced Prostate Cancer: Results from the Phase 3 HERO Study. European Urology Oncology. PMID 38143206 DOI: 10.1016/j.euo.2023.11.024 |
0.429 |
|
| 2023 |
Small EJ, Chi KN, Chowdhury S, Bevans KB, Bhaumik A, Saad F, Chung BH, Karsh LI, Oudard S, De Porre P, Brookman-May SD, McCarthy SA, Mundle SD, Uemura H, Smith MR, et al. Post Hoc Analysis of Rapid and Deep Prostate-specific Antigen Decline and Patient-reported Health-related Quality of Life in SPARTAN and TITAN Patients with Advanced Prostate Cancer. European Urology Oncology. PMID 38072759 DOI: 10.1016/j.euo.2023.11.015 |
0.479 |
|
| 2023 |
Saad F, Del Rosario P, Clarke NW. Reply to Lin Ding, Bin Yang, and Xudong Yao's Letter to the Editor re: Fred Saad, Noel W. Clarke, Mototsugu Oya, et al. Olaparib plus Abiraterone Versus Placebo plus Abiraterone in Metastatic Castration-resistant Prostate Cancer (PROpel): Final Prespecified Overall Survival Results of a Randomised, Double-blind, Phase 3 Trial. Lancet Oncol 2023;24:1094-108. European Urology. PMID 38042647 DOI: 10.1016/j.eururo.2023.11.015 |
0.36 |
|
| 2023 |
Mateo J, de Bono JS, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Agarwal N, Olmos D, Thiery-Vuillemin A, Özgüroğlu M, Mehra N, Matsubara N, Young Joung J, Padua C, et al. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in and/or in the PROfound Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300339. PMID 37963304 DOI: 10.1200/JCO.23.00339 |
0.478 |
|
| 2023 |
Shen J, Chowdhury S, Agarwal N, Karsh LI, Oudard S, Gartrell BA, Feyerabend S, Saad F, Pieczonka CM, Chi KN, Brookman-May SD, Rooney B, Bhaumik A, McCarthy SA, Bevans KB, et al. Apalutamide efficacy, safety and wellbeing in older patients with advanced prostate cancer from Phase 3 randomised clinical studies TITAN and SPARTAN. British Journal of Cancer. PMID 37951974 DOI: 10.1038/s41416-023-02492-8 |
0.477 |
|
| 2023 |
Roy S, Malone S, Sun Y, Zaorsky NG, Spratt DE, Morgan SC, Dess RT, Wallis CJD, Kishan AU, Citrin DE, Saad F. Effect of Pelvic External Beam Radiation Therapy on Bone Mineral Density: A Secondary Analysis of a Phase III Randomized Controlled Trial. International Journal of Radiation Oncology, Biology, Physics. PMID 37924987 DOI: 10.1016/j.ijrobp.2023.10.046 |
0.416 |
|
| 2023 |
Agarwal N, Saad F, Azad AA, Mateo J, Matsubara N, Shore ND, Chakrabarti J, Chen HC, Lanzalone S, Niyazov A, Fizazi K. TALAPRO-3 clinical trial protocol: phase III study of talazoparib plus enzalutamide in metastatic castration-sensitive prostate cancer. Future Oncology (London, England). PMID 37882449 DOI: 10.2217/fon-2023-0526 |
0.457 |
|
| 2023 |
Scheipner L, Incesu RB, Morra S, Baudo A, Assad A, Jannello LMI, Siech C, de Angelis M, Barletta F, Tian Z, Saad F, Shariat SF, Briganti A, Chun FKH, Tilki D, et al. Characteristics of incidental prostate cancer in the United States. Prostate Cancer and Prostatic Diseases. PMID 37872250 DOI: 10.1038/s41391-023-00742-7 |
0.498 |
|
| 2023 |
Rendon RA, Selvarajah S, Wyatt AW, Kolinsky M, Schrader KA, Fleshner NE, Kinnaird A, Merrimen J, Niazi T, Saad F, Shayegan B, Wood L, Chi KN, Black P, Sridhar S, et al. 2023 Canadian Urological Association guideline: Genetic testing in prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 17: 314-325. PMID 37851913 DOI: 10.5489/cuaj.8588 |
0.435 |
|
| 2023 |
Saad F, George DJ, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Tombal B, Shore ND. Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer. Cancers. 15. PMID 37835548 DOI: 10.3390/cancers15194854 |
0.451 |
|
| 2023 |
Shore ND, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Tombal B, Nordquist L, Cookson M, Verholen F, Jhaveri J, Srinivasan S, Smith MR. Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS Trial. The Oncologist. PMID 37812679 DOI: 10.1093/oncolo/oyad254 |
0.378 |
|
| 2023 |
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, et al. Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial. The Lancet. Oncology. PMID 37714168 DOI: 10.1016/S1470-2045(23)00382-0 |
0.435 |
|
| 2023 |
Shore ND, Mehlhaff BA, Cookson MS, Saltzstein DR, Tutrone R, Brown B, Lu S, Fallick M, Hanson S, Saad F. Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate Cancer. Advances in Therapy. PMID 37713020 DOI: 10.1007/s12325-023-02634-7 |
0.446 |
|
| 2023 |
Tappero S, Piccinelli ML, Incesu RB, Cano Garcia C, Barletta F, Morra S, Scheipner L, Baudo A, Tian Z, Parodi S, Dell'Oglio P, de Cobelli O, Graefen M, Chun FKH, Briganti A, ... ... Saad F, et al. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites. Clinical Genitourinary Cancer. PMID 37690970 DOI: 10.1016/j.clgc.2023.08.004 |
0.449 |
|
| 2023 |
Roy S, Sun Y, Wallis CJD, Kishan AU, Morgan SC, Spratt DE, Malone S, Saad F. Prognostic Role of Dynamic Changes in Serological Markers in Metastatic Hormone Naïve Prostate Cancer. Cancers. 15. PMID 37686668 DOI: 10.3390/cancers15174392 |
0.354 |
|
| 2023 |
Agarwal N, Zhang T, Efstathiou E, Sayegh N, Engelsberg A, Saad F, Fizazi K. The biology behind combining poly [ADP ribose] polymerase and androgen receptor inhibition for metastatic castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 192: 113249. PMID 37672815 DOI: 10.1016/j.ejca.2023.113249 |
0.414 |
|
| 2023 |
Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, et al. Correction to: Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer and Prostatic Diseases. PMID 37620428 DOI: 10.1038/s41391-023-00683-1 |
0.488 |
|
| 2023 |
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, Giorgi U, Shore ND, Saad F. Plain Language Summary: Can declines in prostate-specific antigen level indicate how long patients with advanced prostate cancer will live when treated with enzalutamide? Future Oncology (London, England). PMID 37585665 DOI: 10.2217/fon-2023-0135 |
0.557 |
|
| 2023 |
Yip SM, Morash C, Kolinsky MP, Kapoor A, Ong M, Selvarajah S, Nuk J, Compton K, Pouliot F, Lavallée LT, Khalaf DJ, Hamilton RJ, Gotto GT, Rendon RA, Antebi E, ... ... Saad F, et al. Genetic testing practices among specialist physicians who treat prostate cancer: A Canadian cross-sectional survey. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 37494316 DOI: 10.5489/cuaj.8403 |
0.399 |
|
| 2023 |
Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Gallucci M, Briganti A, Montorsi F, Chun FKH, Graefen M, Shariat SF, Guano G, Mantica G, et al. The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. Central European Journal of Urology. 76: 104-108. PMID 37483849 DOI: 10.5173/ceju.2023.030 |
0.4 |
|
| 2023 |
Smith MR, Sandhu S, George DJ, Chi KN, Saad F, Thiery-Vuillemin A, Stàhl O, Olmos D, Danila DC, Gafanov R, Castro E, Moon H, Joshua AM, Mason GE, Espina BM, et al. Health-related quality of life in GALAHAD: A multicenter, open-label, phase 2 study of niraparib for patients with metastatic castration-resistant prostate cancer and DNA-repair gene defects. Journal of Managed Care & Specialty Pharmacy. 29: 758-768. PMID 37404070 DOI: 10.18553/jmcp.2023.29.7.758 |
0.334 |
|
| 2023 |
Kim JS, Taaffe DR, Galvão DA, Saad F, Newton RU. Exercise Mediates Myokine Release and Tumor Suppression in Prostate Cancer Independent of Androgen Signaling. Exercise and Sport Sciences Reviews. PMID 37288965 DOI: 10.1249/JES.0000000000000323 |
0.388 |
|
| 2023 |
Higano CS, George DJ, Shore ND, Sartor O, Miller K, Conti PS, Sternberg CN, Saad F, Sade JP, Bellmunt J, Smith MR, Chandrawansa K, Sandström P, Verholen F, Tombal B. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. Eclinicalmedicine. 60: 101993. PMID 37251627 DOI: 10.1016/j.eclinm.2023.101993 |
0.454 |
|
| 2023 |
Petersen PM, Cook AD, Sydes MR, Clarke N, Cross W, Kynaston H, Logue J, Neville P, Payne H, Parmar MK, Parulekar W, Persad R, Saad F, Stirling A, Parker CC, et al. Salvage radiotherapy after radical prostatectomy: analysis of toxicity by dose-fractionation in the RADICALS-RT trial. International Journal of Radiation Oncology, Biology, Physics. PMID 37150260 DOI: 10.1016/j.ijrobp.2023.04.032 |
0.333 |
|
| 2023 |
Roy S, Wallis CJD, Morgan SC, Kishan AU, Le ATT, Malone J, Sun Y, Spratt DE, Saad F, Malone S. Implications of metastatic stage at presentation in docetaxel naïve metastatic castrate resistant prostate cancer. The Prostate. PMID 37071764 DOI: 10.1002/pros.24512 |
0.498 |
|
| 2023 |
George DJ, Saad F, Cookson MS, Saltzstein DR, Tutrone R, Bossi A, Brown B, Selby B, Lu S, Buckley D, Tombal B, Shore ND. Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. Clinical Genitourinary Cancer. PMID 37062659 DOI: 10.1016/j.clgc.2023.03.009 |
0.505 |
|
| 2023 |
Halabi S, Yang Q, Roy A, Luo B, Araujo JC, Logothetis C, Sternberg CN, Armstrong AJ, Carducci MA, Chi KN, de Bono JS, Petrylak DP, Fizazi K, Higano CS, Morris MJ, ... ... Saad F, et al. External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2202661. PMID 37040594 DOI: 10.1200/JCO.22.02661 |
0.422 |
|
| 2023 |
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, ... ... Saad F, et al. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. European Journal of Cancer (Oxford, England : 1990). 185: 178-215. PMID 37003085 DOI: 10.1016/j.ejca.2023.02.018 |
0.521 |
|
| 2023 |
Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, Shariat SF, Guano G, Mantica G, et al. The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. The Prostate. PMID 36919872 DOI: 10.1002/pros.24505 |
0.472 |
|
| 2023 |
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer and Prostatic Diseases. PMID 36899091 DOI: 10.1038/s41391-023-00656-4 |
0.408 |
|
| 2023 |
Roy S, Sun Y, Morgan SC, Wallis CJD, King K, Zhou YM, D'souza LA, Azem O, Cueto-Marquez AE, Camden NB, Spratt DE, Kishan AU, Saad F, Malone S. Effect of Prior Local Therapy on Response to First-line Androgen Receptor Axis Targeted Therapy in Metastatic Castrate-resistant Prostate Cancer: A Secondary Analysis of the COU-AA-302 Trial. European Urology. PMID 36894488 DOI: 10.1016/j.eururo.2023.02.017 |
0.442 |
|
| 2023 |
Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Parodi S, Dell'Oglio P, Briganti A, de Cobelli O, Chun FKH, Graefen M, Mirone V, ... ... Saad F, et al. Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer. Urologic Oncology. PMID 36882338 DOI: 10.1016/j.urolonc.2023.01.015 |
0.318 |
|
| 2023 |
Saad F. Editorial for the Special Edition of Advanced Prostate Cancer: From Bench to Bedside. Cancers. 15. PMID 36831589 DOI: 10.3390/cancers15041247 |
0.488 |
|
| 2023 |
Hussain M, Tombal B, Saad F, Fizazi K, Sternberg CN, Crawford ED, Shore N, Kopyltsov E, Kalebasty AR, Bögemann M, Ye D, Cruz F, Suzuki H, Kapur S, Srinivasan S, et al. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2300041. PMID 36795843 DOI: 10.1200/JCO.23.00041 |
0.473 |
|
| 2023 |
Hussain M, Sternberg CN, Efstathiou E, Fizazi K, Shen Q, Lin X, Sugg J, Steinberg J, Noerby B, De Giorgi U, Shore ND, Saad F. Nadir Prostate-specific Antigen as an Independent Predictor of Survival Outcomes: A Post Hoc Analysis of the PROSPER Randomized Clinical Trial. The Journal of Urology. 209: 532-539. PMID 36756959 DOI: 10.1097/JU.0000000000003084 |
0.41 |
|
| 2023 |
So AI, Saad F. 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Summary of changes. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 16: 389-391. PMID 36656701 DOI: 10.5489/cuaj.8159 |
0.478 |
|
| 2023 |
So AI, Chi K, Danielson B, Fleshner NE, Kinnaird A, Kapoor A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, Vigneault E, Saad F. 2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 16: E581-E589. PMID 36656694 DOI: 10.5489/cuaj.8148 |
0.49 |
|
| 2023 |
Petit C, Delouya G, Taussky D, Barkati M, Lambert C, Beauchemin MC, Clavel S, Mok G, Paré AG, Nguyen TV, Duplan D, Visith Keu K, Saad F, Juneau D, Ménard C. PSMA-PET/CT guided intensification of radiotherapy for prostate cancer (PSMAgRT): Findings of detection rate, impact on cancer management, and early toxicity from a phase 2 randomised controlled trial. International Journal of Radiation Oncology, Biology, Physics. PMID 36639035 DOI: 10.1016/j.ijrobp.2022.12.055 |
0.423 |
|
| 2022 |
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, de Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, ... ... Saad F, et al. Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. Nejm Evidence. 1: EVIDoa2200043. PMID 38319800 DOI: 10.1056/EVIDoa2200043 |
0.49 |
|
| 2022 |
Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, Shariat SF, Antonelli A, et al. Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy. Arab Journal of Urology. 21: 135-141. PMID 37521449 DOI: 10.1080/2090598X.2022.2148867 |
0.438 |
|
| 2022 |
Tappero S, Sorce G, Panunzio A, Hohenhorst L, Garcia CC, Piccinelli ML, Tian Z, Parodi S, Chun FKH, Graefen M, Antonelli A, De Cobelli O, Saad F, Shariat SF, Montorsi F, et al. Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients. Central European Journal of Urology. 75: 352-356. PMID 36794025 DOI: 10.5173/ceju.2022.142 |
0.31 |
|
| 2022 |
Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Sorce G, Tian Z, Leonardo C, Graefen M, Terrone C, Saad F, Shariat SF, Briganti A, Montorsi F, Chun FKH, Gallucci M, et al. Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries. Current Urology. 16: 191-196. PMID 36714227 DOI: 10.1097/CU9.0000000000000132 |
0.385 |
|
| 2022 |
Saad F. Debate on Treating Oligometastatic Metastatic Hormone-sensitive Prostate Cancer: The Argument for New-generation Hormone Therapy and Radiation Therapy to the Prostate. European Urology Open Science. 47: 1-2. PMID 36573247 DOI: 10.1016/j.euros.2022.10.020 |
0.451 |
|
| 2022 |
Nocera L, Stolzenbach LF, Collà Ruvolo C, Wenzel M, Wurnschimmel C, Tian Z, Gandaglia G, Fossati N, Mirone V, Chun FKH, Shariat SF, Graefen M, Saad F, Montorsi F, Briganti A, et al. Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerations. Frontiers in Oncology. 12: 990851. PMID 36561531 DOI: 10.3389/fonc.2022.990851 |
0.393 |
|
| 2022 |
Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, ... ... Saad F, et al. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. European Urology. PMID 36494221 DOI: 10.1016/j.eururo.2022.11.002 |
0.521 |
|
| 2022 |
Saad F, Bhindi B, Noonan K, Ong M, Castellano K, Kourkounakis A, Wallis CJD. Assessment of the epidemiological trends for prostate cancer using administrative data in Ontario. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 36486175 DOI: 10.5489/cuaj.8099 |
0.477 |
|
| 2022 |
Tappero S, Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Garcia CC, Piccinelli M, Tian Z, Parodi S, Montorsi F, Chun FKH, Graefen M, Antonelli A, Saad F, Shariat SF, et al. The effect of chemotherapy in sarcomatoid bladder cancer patients treated with radical cystectomy. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 36473471 DOI: 10.5489/cuaj.8056 |
0.341 |
|
| 2022 |
Kim JS, Taaffe DR, Galvão DA, Clay TD, Redfern AD, Hart NH, Gray ES, Ryan CJ, Kenfield SA, Saad F, Newton RU. Acute effect of high-intensity interval aerobic exercise on serum myokine levels and resulting tumour-suppressive effect in trained patients with advanced prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 36446945 DOI: 10.1038/s41391-022-00624-4 |
0.347 |
|
| 2022 |
Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So AI, Usmani N, Vigneault E, et al. 2022 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 16: E506-E515. PMID 36378572 DOI: 10.5489/cuaj.8161 |
0.433 |
|
| 2022 |
Dahmani C, Caron P, Simonyan D, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C. Preoperative Circulating 11-Oxygenated Androgens Are Associated With Metastasis-free Survival in Localized Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 36373402 DOI: 10.1097/JU.0000000000003049 |
0.483 |
|
| 2022 |
Roy S, Saad F. Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors. Current Opinion in Supportive and Palliative Care. 16: 223-229. PMID 36349381 DOI: 10.1097/SPC.0000000000000620 |
0.468 |
|
| 2022 |
Rouleau M, Nguyen Van Long F, Turcotte V, Caron P, Lacombe L, Aprikian A, Saad F, Carmel M, Chevalier S, Lévesque E, Guillemette C. Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancer. British Journal of Cancer. PMID 36347965 DOI: 10.1038/s41416-022-02040-w |
0.363 |
|
| 2022 |
Lacombe L, Hovington H, Brisson H, Mehdi S, Beillevaire D, Émond JP, Wagner A, Villeneuve L, Simonyan D, Ouellet V, Barrès V, Latour M, Aprikian A, Bergeron A, Castonguay V, ... ... Saad F, et al. UGT2B28 accelerates prostate cancer progression through stabilization of the endocytic adaptor protein HIP1 regulating AR and EGFR pathways. Cancer Letters. 215994. PMID 36343786 DOI: 10.1016/j.canlet.2022.215994 |
0.362 |
|
| 2022 |
Bénard F, Harsini S, Wilson D, Zukotynski K, Abikhzer G, Turcotte E, Cossette M, Metser U, Romsa J, Martin M, Mar C, Saad F, Soucy JP, Eigl BJ, Black P, et al. Intra-individual comparison of F-sodium fluoride PET-CT and Tc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial. The Lancet. Oncology. PMID 36343655 DOI: 10.1016/S1470-2045(22)00642-8 |
0.401 |
|
| 2022 |
Panunzio A, Sorce G, Hoeh B, Hohenhorst L, Tappero S, Nimer N, Rajwa P, Tian Z, Terrone C, Chun FKH, Briganti A, Saad F, Shariat SF, Cerruto MA, Antonelli A, et al. Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate cancer patients with Gleason Grade Group 4-5. The Prostate. PMID 36336728 DOI: 10.1002/pros.24458 |
0.465 |
|
| 2022 |
Kaulanjan K, Dahan J, Charrois-Durand C, Saad F, Brureau L, Delouya G, Taussky D, Auclin E. Change of the Neutrophil-to-Lymphocyte Ratio during Treatment: A Potential Prognostic Biomarker in Metastatic Prostate Cancer Treated with Radium-223 Dichloride. Cancers. 14. PMID 36230529 DOI: 10.3390/cancers14194606 |
0.364 |
|
| 2022 |
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide? Future Oncology (London, England). PMID 36226865 DOI: 10.2217/fon-2022-0661 |
0.53 |
|
| 2022 |
Pollock Y, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik B, Olmos D, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney B, Brookman-May SD, De Porre P, Mundle SD, et al. Clinical characteristics associated with falls in patients with non-metastatic castration-resistant prostate cancer treated with apalutamide. Prostate Cancer and Prostatic Diseases. PMID 36209239 DOI: 10.1038/s41391-022-00592-9 |
0.487 |
|
| 2022 |
Tappero S, Panunzio A, Hohenhorst L, Cano Garcia C, Barletta F, Piccinelli M, Tian Z, Parodi S, Antonelli A, Graefen M, Chun FKH, Briganti A, De Cobelli O, Saad F, Shariat SF, et al. Radical cystectomy in non-metastatic sarcomatoid bladder cancer: A direct comparison vs urothelial bladder cancer. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. PMID 36192262 DOI: 10.1016/j.ejso.2022.09.013 |
0.353 |
|
| 2022 |
Roy S, Morgan SC, Wallis CJD, Sun Y, Spratt DE, Malone J, Grimes S, Mukherjee D, Kishan AU, Saad F, Malone S. Association of dynamic change in patient-reported pain with survival in metastatic castrate sensitive prostate cancer-exploratory analysis of LATITUDE study. Prostate Cancer and Prostatic Diseases. PMID 36097167 DOI: 10.1038/s41391-022-00529-2 |
0.392 |
|
| 2022 |
Saad F, Thiery-Vuillemin A, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Kang J, Burgents J, Gresty C, Degboe A, et al. Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial. The Lancet. Oncology. PMID 36063830 DOI: 10.1016/S1470-2045(22)00498-3 |
0.439 |
|
| 2022 |
Cahuzac M, Péant B, Mes-Masson AM, Saad F. Development of Olaparib-Resistance Prostate Cancer Cell Lines to Identify Mechanisms Associated with Acquired Resistance. Cancers. 14. PMID 36010871 DOI: 10.3390/cancers14163877 |
0.334 |
|
| 2022 |
Morris MJ, Mota JM, Lacuna K, Hilden P, Gleave M, Carducci MA, Saad F, Cohn ED, Filipenko J, Heller G, Shore N, Armstrong AJ, Scher HI. Erratum to "Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)" [Eur Urol Oncol 2021;4:543-52]. European Urology Oncology. PMID 35985981 DOI: 10.1016/j.euo.2022.08.001 |
0.427 |
|
| 2022 |
Fizazi K, Retz M, Petrylak DP, Goh JC, Perez-Gracia J, Lacombe L, Zschäbitz S, Burotto M, Mahammedi H, Gravis G, Bastos DA, McCune SL, Vázquez Limón JC, Kwan EM, Castellano D, ... ... Saad F, et al. Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial. Journal For Immunotherapy of Cancer. 10. PMID 35977756 DOI: 10.1136/jitc-2022-004761 |
0.407 |
|
| 2022 |
Malone S, Wallis CJD, Lee-Ying R, Basappa NS, Cagiannos I, Hamilton RJ, Fernandes R, Ferrario C, Gotto GT, Morgan SC, Morash C, Niazi T, Noonan KL, Rendon R, Hotte SJ, ... Saad F, et al. Patterns of care for non-metastatic castration-resistant prostate cancer: A population-based study. Bjui Compass. 3: 383-391. PMID 35950037 DOI: 10.1002/bco2.158 |
0.458 |
|
| 2022 |
Kaulanjan K, Lavigne D, Saad F, Karakiewicz PI, Flammia RS, Kluth LA, Mandel P, Chun FK, Taussky D, Hoeh B. Impact of Statin Use on Localized Prostate Cancer Outcomes after Radiation Therapy: Long-Term Follow-Up. Cancers. 14. PMID 35892865 DOI: 10.3390/cancers14153606 |
0.341 |
|
| 2022 |
Wenzel M, Collà Ruvolo C, Würnschimmel C, Nocera L, Hoeh B, Tian Z, Saad F, Briganti A, Tilki D, Banek S, Mandel P, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Epidemiology of Unconventional Histological Subtypes of Urethral Cancer. Urologia Internationalis. 1-8. PMID 35882213 DOI: 10.1159/000525673 |
0.319 |
|
| 2022 |
Tisseverasinghe S, Tolba M, Saad F, Gravis G, Bahoric B, Niazi T. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200883. PMID 35862876 DOI: 10.1200/JCO.22.00883 |
0.412 |
|
| 2022 |
Flammia RS, Hoeh B, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Leonardo C, Briganti A, Antonelli A, Terrone C, Shariat SF, Anceschi U, Graefen M, et al. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. International Urology and Nephrology. PMID 35838831 DOI: 10.1007/s11255-022-03250-0 |
0.445 |
|
| 2022 |
Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat SF, Graefen M, Tilki D, Kluth LA, Mandel P, et al. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. Urologic Oncology. PMID 35817649 DOI: 10.1016/j.urolonc.2022.06.003 |
0.425 |
|
| 2022 |
Roy S, Sayyid R, Saad F, Sun Y, Lajkosz K, Ong M, Klaassen Z, Malone S, Spratt DE, Wallis CJD, Morgan SC. Addition of Docetaxel to Androgen Receptor Axis-targeted Therapy and Androgen Deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer: A Network Meta-analysis. European Urology Oncology. PMID 35811293 DOI: 10.1016/j.euo.2022.06.003 |
0.424 |
|
| 2022 |
Roy S, Sun Y, Wallis CJD, Morgan SC, Grimes S, Malone J, Kishan AU, Mukherjee D, Spratt DE, Saad F, Malone S. Development and validation of a multivariable prognostic model in de novo metastatic castrate sensitive prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 35790787 DOI: 10.1038/s41391-022-00560-3 |
0.414 |
|
| 2022 |
Saad F, de Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels JP, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, et al. Patient-reported Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Harboring DNA Damage Response Alterations Treated with Talazoparib: Results from TALAPRO-1. European Urology. PMID 35750582 DOI: 10.1016/j.eururo.2022.05.030 |
0.42 |
|
| 2022 |
Geoffroy K, Laplante P, Clairefond S, Azzi F, Trudel D, Lattouf JB, Stagg J, Saad F, Mes-Masson AM, Bourgeois-Daigneault MC, Cailhier JF. High Levels of MFG-E8 Confer a Good Prognosis in Prostate and Renal Cancer Patients. Cancers. 14. PMID 35681775 DOI: 10.3390/cancers14112790 |
0.362 |
|
| 2022 |
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford D, Manarite J, Muslin D, Farrington T, Tombal B. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer: a patient and caregiver perspective and plain language summary of the ARASENS study. Future Oncology (London, England). PMID 35656777 DOI: 10.2217/fon-2022-0433 |
0.54 |
|
| 2022 |
Sorce G, Hoeh B, Flammia RS, Chierigo F, Hohenhorst L, Panunzio A, Nimer N, Tian Z, Gandaglia G, Tilki D, Terrone C, Gallucci M, Chun FKH, Antonelli A, Saad F, et al. Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. The Prostate. 82: 1210-1218. PMID 35652586 DOI: 10.1002/pros.24376 |
0.438 |
|
| 2022 |
Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Tilki D, Gallucci M, Briganti A, Montorsi F, Chun FKH, Shariat SF, et al. Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. Clinical Genitourinary Cancer. PMID 35618597 DOI: 10.1016/j.clgc.2022.04.005 |
0.46 |
|
| 2022 |
Roubaud G, Özgüroğlu M, Penel N, Matsubara N, Mehra N, Kolinsky MP, Procopio G, Feyerabend S, Joung JY, Gravis G, Nishimura K, Gedye C, Padua C, Shore N, Thiery-Vuillemin A, ... Saad F, et al. Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. European Journal of Cancer (Oxford, England : 1990). 170: 73-84. PMID 35598359 DOI: 10.1016/j.ejca.2022.04.016 |
0.465 |
|
| 2022 |
Wilson BE, Armstrong AJ, de Bono J, Sternberg CN, Ryan CJ, Scher HI, Smith MR, Rathkopf D, Logothetis CJ, Chi KN, Jones RJ, Saad F, De Porre P, Tran N, Hu P, et al. Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. European Journal of Cancer (Oxford, England : 1990). PMID 35568679 DOI: 10.1016/j.ejca.2022.03.042 |
0.493 |
|
| 2022 |
Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Hoeh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, Shariat SF, et al. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. International Urology and Nephrology. 54: 1521-1527. PMID 35508792 DOI: 10.1007/s11255-022-03221-5 |
0.313 |
|
| 2022 |
Saad F, Chilelli A, Hui B, Muratov S, Ganguli A, North S, Shayegan B. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. Journal of Medical Economics. 25: 583-590. PMID 35469527 DOI: 10.1080/13696998.2022.2066850 |
0.445 |
|
| 2022 |
Rajwa P, Pradere B, Gandaglia G, van den Bergh RCN, Tsaur I, Shim SR, Yanagisawa T, Laukhtina E, Mori K, Mostafaei H, Quhal F, Bryniarski P, Compérat E, Roubaud G, Massard C, ... ... Saad F, et al. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. European Urology. 82: 82-96. PMID 35465985 DOI: 10.1016/j.eururo.2022.03.031 |
0.484 |
|
| 2022 |
Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, ... ... Saad F, et al. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology. PMID 35450732 DOI: 10.1016/j.eururo.2022.04.002 |
0.511 |
|
| 2022 |
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, ... ... Saad F, et al. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 2022]. European Urology. PMID 35440417 DOI: 10.1016/j.eururo.2022.04.004 |
0.506 |
|
| 2022 |
Hussain M, Carducci MA, Clarke N, Fenton SE, Fizazi K, Gillessen S, Jacene H, Morris MJ, Saad F, Sartor O, Taplin ME, Vapiwala N, Williams S, Sweeney C. Evolving Role of Prostate-Specific Membrane Antigen-Positron Emission Tomography in Metastatic Hormone-Sensitive Prostate Cancer: More Questions than Answers? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2200208. PMID 35439030 DOI: 10.1200/JCO.22.00208 |
0.431 |
|
| 2022 |
Dariane C, Clairefond S, Péant B, Communal L, Thian Z, Ouellet V, Trudel D, Benzerdjeb N, Azzi F, Méjean A, Timsit MO, Baurès M, Guidotti JE, Goffin V, Karakiewicz PI, ... ... Saad F, et al. High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality. Cancers. 14. PMID 35406395 DOI: 10.3390/cancers14071623 |
0.522 |
|
| 2022 |
Flammia RS, Hoeh B, Sorce G, Chierigo F, Hohenhorst L, Tian Z, Goyal JA, Leonardo C, Briganti A, Graefen M, Terrone C, Saad F, Shariat SF, Montorsi F, Chun FKH, et al. Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients. The Prostate. PMID 35403734 DOI: 10.1002/pros.24350 |
0.442 |
|
| 2022 |
Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, ... ... Saad F, et al. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. European Urology. PMID 35393158 DOI: 10.1016/j.eururo.2022.02.010 |
0.479 |
|
| 2022 |
Sorce G, Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Panunzio A, Stabile A, Gandaglia G, Tian Z, Tilki D, Terrone C, Gallucci M, Chun FKH, Antonelli A, Saad F, et al. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. The Prostate. PMID 35365851 DOI: 10.1002/pros.24349 |
0.472 |
|
| 2022 |
Mason RJ, Marzouk K, Finelli A, Saad F, So AI, Violette PD, Breau RH, Rendon RA. UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 16: E184-E196. PMID 35358414 DOI: 10.5489/cuaj.7851 |
0.431 |
|
| 2022 |
Mason RJ, Marzouk K, Finelli A, Saad F, So AI, Violette PD, Breau RH, Rendon RA. UPDATE - 2022 Canadian Urological Association recommendations on prostate cancer screening and early diagnosis Endorsement of the 2021 Cancer Care Ontario guidelines on prostate multiparametric magnetic resonance imaging - Summary of changes. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 16: 86-87. PMID 35358410 DOI: 10.5489/cuaj.7832 |
0.429 |
|
| 2022 |
Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat SF, Graefen M, Tilki D, Kluth LA, Mandel P, et al. Up- and downgrading in single intermediate-risk positive biopsy core prostate cancer. Prostate International. 10: 21-27. PMID 35261911 DOI: 10.1016/j.prnil.2022.01.004 |
0.326 |
|
| 2022 |
Ménard C, Young S, Zukotynski K, Hamilton RJ, Bénard F, Yip S, McCabe C, Saad F, Brundage M, Nitulescu R, Bauman G. PSMA PET/CT guided intensification of therapy in patients at risk of advanced prostate cancer (PATRON): a pragmatic phase III randomized controlled trial. Bmc Cancer. 22: 251. PMID 35260100 DOI: 10.1186/s12885-022-09283-z |
0.399 |
|
| 2022 |
Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Horlemann B, Tian Z, Saad F, Briganti A, Shariat SF, Gallucci M, Suardi N, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. Cancer Causes & Control : Ccc. PMID 35230576 DOI: 10.1007/s10552-022-01564-z |
0.358 |
|
| 2022 |
Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Hoeh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, Shariat SF, et al. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. The Prostate. PMID 35226380 DOI: 10.1002/pros.24317 |
0.415 |
|
| 2022 |
Shayegan B, Wallis CJD, Malone S, Cagiannos I, Hamilton RJ, Ferrario C, Gotto GT, Basappa NS, Morgan SC, Fernandes R, Morash C, Niazi T, Noonan KL, Rendon R, Osborne B, ... ... Saad F, et al. Real-world use of systemic therapies in men with metastatic castration resistant prostate cancer (mCRPC) in Canada. Urologic Oncology. PMID 35216890 DOI: 10.1016/j.urolonc.2022.01.009 |
0.467 |
|
| 2022 |
Shayegan B, Wallis CJD, Hamilton RJ, Morgan SC, Cagiannos I, Basappa NS, Ferrario C, Gotto GT, Fernandes R, Roy S, Noonan KL, Niazi T, Hotte SJ, Saad F, Hew H, et al. Real-world utilization and outcomes of docetaxel among older men with metastatic prostate cancer: a retrospective population-based cohort study in Canada. Prostate Cancer and Prostatic Diseases. PMID 35197558 DOI: 10.1038/s41391-022-00514-9 |
0.466 |
|
| 2022 |
George DJ, Agarwal N, Sartor O, Sternberg CN, Tombal B, Saad F, Miller K, Constantinovici N, Guo H, Reeves J, Jiao X, Sandström P, Verholen F, Higano CS, Shore N. Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). Prostate Cancer and Prostatic Diseases. PMID 35190653 DOI: 10.1038/s41391-021-00488-0 |
0.462 |
|
| 2022 |
Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, Briganti A, Terrone C, Shariat SF, Graefen M, Tilki D, Kluth LA, Mandel P, et al. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. The Prostate. PMID 35188982 DOI: 10.1002/pros.24313 |
0.42 |
|
| 2022 |
Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Tilki D, Kluth LA, et al. Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. The Prostate. PMID 35188981 DOI: 10.1002/pros.24312 |
0.474 |
|
| 2022 |
Würnschimmel C, Nocera L, Wenzel M, Ruvolo CC, Tian Z, Saad F, Briganti A, Shariat SF, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. Journal of Racial and Ethnic Health Disparities. PMID 35182370 DOI: 10.1007/s40615-022-01257-y |
0.373 |
|
| 2022 |
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, et al. Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. The New England Journal of Medicine. PMID 35179323 DOI: 10.1056/NEJMoa2119115 |
0.506 |
|
| 2022 |
Thiery-Vuillemin A, de Bono J, Hussain M, Roubaud G, Procopio G, Shore N, Fizazi K, Dos Anjos G, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, ... ... Saad F, et al. Pain and health-related quality of life with olaparib versus physician's choice of next-generation hormonal drug in patients with metastatic castration-resistant prostate cancer with homologous recombination repair gene alterations (PROfound): an open-label, randomised, phase 3 trial. The Lancet. Oncology. PMID 35157830 DOI: 10.1016/S1470-2045(22)00017-1 |
0.389 |
|
| 2022 |
Kim JS, Taaffe DR, Galvão DA, Hart NH, Gray E, Ryan CJ, Kenfield SA, Saad F, Newton RU. Exercise in advanced prostate cancer elevates myokine levels and suppresses in-vitro cell growth. Prostate Cancer and Prostatic Diseases. PMID 35152272 DOI: 10.1038/s41391-022-00504-x |
0.342 |
|
| 2022 |
Ouellet V, Erickson A, Wiley K, Morrissey C, Berge V, Moreno CS, Tasken KA, Trudel D, True LD, Lewis MS, Svindland A, Ertunc O, Vidal ID, Osunkoya AO, Jones T, ... ... Saad F, et al. The Movember Global Action Plan 1 (GAP1) - Unique Prostate Cancer Tissue Microarray Resource. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 35131885 DOI: 10.1158/1055-9965.EPI-21-0600 |
0.412 |
|
| 2022 |
Smith MR, Scher HI, Sandhu S, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Ståhl O, Olmos D, Danila DC, Mason GE, Espina BM, Zhao X, et al. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial. The Lancet. Oncology. PMID 35131040 DOI: 10.1016/S1470-2045(21)00757-9 |
0.444 |
|
| 2022 |
Charrois-Durand C, Saad F, Barkati M, Lattouf JB, Perrotte P, Karakiewicz PI, Soulières D, Blais N, Hamilou Z, Juneau D, Plouznikoff N, Taussky D, Delouya G. A single-center, multidisciplinary experience with radium-223 dichloride in men with metastatic castrate-resistant prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 35099384 DOI: 10.5489/cuaj.7591 |
0.46 |
|
| 2022 |
Saad F. Improving outcomes of men with incurable prostate cancer. Lancet (London, England). 399: 413-415. PMID 35093214 DOI: 10.1016/S0140-6736(22)00148-9 |
0.435 |
|
| 2022 |
Hussain M, Corcoran C, Sibilla C, Fizazi K, Saad F, Shore N, Sandhu S, Mateo J, Olmos D, Mehra N, Kolinsky MP, Roubaud G, Ӧzgüroǧlu M, Matsubara N, Gedye C, et al. Tumor Genomic Testing for >4000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35091440 DOI: 10.1158/1078-0432.CCR-21-3940 |
0.429 |
|
| 2022 |
Sorce G, Flammia RS, Hoeh B, Chierigo F, Horlemann B, Würnschimmel C, Tian Z, Graefen M, Terrone C, Gallucci M, Chun FKH, Saad F, Shariat SF, Montorsi F, Briganti A, et al. Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. World Journal of Urology. PMID 35084543 DOI: 10.1007/s00345-022-03940-5 |
0.303 |
|
| 2022 |
Di Lalla V, Kucharczyk MJ, Wyatt AW, Feng FY, Probst S, Gravis G, So J, Saad F, Niazi T. Quality and Quantity: Evaluating Tumor Biology Alongside Novel Imaging on Diagnosis of Metastatic Hormone-sensitive Prostate Cancer. European Urology. PMID 35065838 DOI: 10.1016/j.eururo.2021.12.038 |
0.385 |
|
| 2022 |
Agarwal N, Azad A, Carles J, Chowdhury S, McGregor B, Merseburger AS, Oudard S, Saad F, Soares A, Benzaghou F, Kerloeguen Y, Kimura A, Mohamed N, Panneerselvam A, Wang F, et al. A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. Future Oncology (London, England). PMID 35034502 DOI: 10.2217/fon-2021-1096 |
0.404 |
|
| 2022 |
Saad F, De Porre P, Brookman-May S, Li J, McCarthy SA, Rathkopf DE. Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply. The Lancet. Oncology. 23: e5-e6. PMID 34973233 DOI: 10.1016/S1470-2045(21)00723-3 |
0.47 |
|
| 2022 |
Zhao JL, Fizazi K, Saad F, Chi KN, Taplin ME, Sternberg CN, Armstrong AJ, de Bono JS, Duggan WT, Scher HI. The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 28: 860-869. PMID 34965947 DOI: 10.1158/1078-0432.CCR-21-1090 |
0.514 |
|
| 2021 |
Cailleteau A, Sargos P, Saad F, Latorzeff I, Supiot S. Drug Intensification in Future Postoperative Radiotherapy Practice in Biochemically-Relapsing Prostate Cancer Patients. Frontiers in Oncology. 11: 780507. PMID 35004302 DOI: 10.3389/fonc.2021.780507 |
0.503 |
|
| 2021 |
Diop MK, Albadine R, Kougioumoutzakis A, Delvoye N, Hovington H, Bergeron A, Fradet Y, Saad F, Trudel D. Identification of Morphologic Criteria Associated with Biochemical Recurrence in Intraductal Carcinoma of the Prostate. Cancers. 13. PMID 34944863 DOI: 10.3390/cancers13246243 |
0.338 |
|
| 2021 |
Wallis CJD, Malone S, Cagiannos I, Morgan SC, Hamilton RJ, Basappa NS, Ferrario C, Gotto GT, Fernandes R, Niazi T, Noonan KL, Saad F, Hotte SJ, Hew H, Chan KFY, et al. Real-World Use of Androgen-Deprivation Therapy: Intensification Among Older Canadian Men With de Novo Metastatic Prostate Cancer. Jnci Cancer Spectrum. 5: pkab082. PMID 34926988 DOI: 10.1093/jncics/pkab082 |
0.456 |
|
| 2021 |
Saad F, Small EJ, Feng FY, Graff JN, Olmos D, Hadaschik BA, Oudard S, Londhe A, Bhaumik A, Lopez-Gitlitz A, Thomas S, Mundle SD, Chowdhury S, Smith MR. Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. European Urology. PMID 34916086 DOI: 10.1016/j.eururo.2021.11.020 |
0.471 |
|
| 2021 |
Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Tilki D, Kluth LA, et al. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. Frontiers in Oncology. 11: 778858. PMID 34888250 DOI: 10.3389/fonc.2021.778858 |
0.458 |
|
| 2021 |
Tombal B, Stenzl A, Cella D, Loriot Y, Armstrong AJ, Fizazi K, Beer T, Sternberg CN, Hussain M, Ivanescu C, Ganguli A, Ramaswamy K, Saad F. The Impact of Enzalutamide on the Prostate Cancer Patient Experience: A Summary Review of Health-Related Quality of Life across Pivotal Clinical Trials. Cancers. 13. PMID 34884981 DOI: 10.3390/cancers13235872 |
0.467 |
|
| 2021 |
Lavallée LT, McLarty R, Tran C, Breau RH, Richard P, Shayegan B, Danielson B, Jammal MP, Saad F, Lam TB, Mason R. Canadian Urological Association best practice report: Bone health in prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 15: 375-382. PMID 34847342 DOI: 10.5489/cuaj.7660 |
0.398 |
|
| 2021 |
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Hollis S, Dougherty B, Harrington EA, Kang J, Saad F, Sala N, Thiery-Vuillemin A, Clarke NW, Hodgson D, et al. Homologous Recombination Repair Gene Mutation Characterization by Liquid Biopsy: A Phase II Trial of Olaparib and Abiraterone in Metastatic Castrate-Resistant Prostate Cancer. Cancers. 13. PMID 34830984 DOI: 10.3390/cancers13225830 |
0.346 |
|
| 2021 |
Kolinsky MP, Niederhoffer KY, Kwan EM, Hotte SJ, Hamilou Z, Yip SM, Chi KN, Wyatt AW, Saad F. Considerations on the identification and management of metastatic prostate cancer patients with DNA repair gene alterations in the Canadian context. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 34812730 DOI: 10.5489/cuaj.7621 |
0.388 |
|
| 2021 |
Fizazi K, González Mella P, Castellano D, Minatta JN, Rezazadeh Kalebasty A, Shaffer D, Vázquez Limón JC, Sánchez López HM, Armstrong AJ, Horvath L, Bastos DA, Amin NP, Li J, Unsal-Kacmaz K, Retz M, ... Saad F, et al. Nivolumab plus docetaxel in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: results from the phase II CheckMate 9KD trial. European Journal of Cancer (Oxford, England : 1990). PMID 34802864 DOI: 10.1016/j.ejca.2021.09.043 |
0.49 |
|
| 2021 |
Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Höh B, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Montorsi F, Chun FKH, Shariat SF, et al. Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. International Urology and Nephrology. PMID 34797483 DOI: 10.1007/s11255-021-03070-8 |
0.428 |
|
| 2021 |
Würnschimmel C, Wenzel M, Chierigo F, Simone Flammia R, Tian Z, Saad F, Briganti A, Shariat SF, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 34788899 DOI: 10.1111/iju.14743 |
0.436 |
|
| 2021 |
De Giorgi U, Hussain M, Shore N, Fizazi K, Tombal B, Penson D, Saad F, Efstathiou E, Madziarska K, Steinberg J, Sugg J, Lin X, Shen Q, Sternberg CN. Consistent survival benefit of enzalutamide plus androgen deprivation therapy in men with nonmetastatic castration-resistant prostate cancer: PROSPER subgroup analysis by age and region. European Journal of Cancer (Oxford, England : 1990). 159: 237-246. PMID 34784577 DOI: 10.1016/j.ejca.2021.10.015 |
0.493 |
|
| 2021 |
Hoeh B, Hohenhorst JL, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Kluth LA, Becker A, et al. Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. International Urology and Nephrology. PMID 34783982 DOI: 10.1007/s11255-021-03055-7 |
0.441 |
|
| 2021 |
Plante A, Dallaire F, Grosset AA, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, ... ... Saad F, et al. Dimensional reduction based on peak fitting of Raman micro spectroscopy data improves detection of prostate cancer in tissue specimens. Journal of Biomedical Optics. 26. PMID 34743445 DOI: 10.1117/1.JBO.26.11.116501 |
0.447 |
|
| 2021 |
Wenzel M, Nocera L, Würnschimmel C, Collà Ruvolo C, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Becker A, Roos FC, Chun FKH, Karakiewicz PI. The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. Frontiers in Oncology. 11: 754996. PMID 34692543 DOI: 10.3389/fonc.2021.754996 |
0.44 |
|
| 2021 |
Pouliot F, Beauregard JM, Saad F, Trudel D, Richard PO, Turcotte É, Rousseau É, Probst S, Kassouf W, Anidjar M, Camirand Lemyre F, Bouvet GF, Neveu B, Tétu A, Guérin B. The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. Bju International. PMID 34674367 DOI: 10.1111/bju.15621 |
0.398 |
|
| 2021 |
Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Kluth LA, Mandel P, et al. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. The Prostate. PMID 34662443 DOI: 10.1002/pros.24253 |
0.342 |
|
| 2021 |
Sartor O, George D, Tombal B, Agarwal N, Higano CS, Sternberg CN, Miller K, Jiao X, Guo H, Sandström P, Bruno A, Verholen F, Saad F, Shore N. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. Future Oncology (London, England). PMID 34636627 DOI: 10.2217/fon-2021-0886 |
0.304 |
|
| 2021 |
Wenzel M, Collà Ruvolo C, Würnschimmel C, Nocera L, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Becker A, Roos F, Mandel P, Chun FKH, Karakiewicz PI. Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. The Prostate. PMID 34633102 DOI: 10.1002/pros.24249 |
0.425 |
|
| 2021 |
Saad F, Efstathiou E, Attard G, Flaig TW, Franke F, Goodman OB, Oudard S, Steuber T, Suzuki H, Wu D, Yeruva K, De Porre P, Brookman-May S, Li S, Li J, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. The Lancet. Oncology. PMID 34600602 DOI: 10.1016/S1470-2045(21)00402-2 |
0.445 |
|
| 2021 |
Chierigo F, Wenzel M, Würnschimmel C, Flammia RS, Horlemann B, Tian Z, Saad F, Chun FKH, Graefen M, Gallucci M, Shariat SF, Mantica G, Borghesi M, Suardi N, Terrone C, et al. Survival after Radical Prostatectomy vs. Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 34555930 DOI: 10.1097/JU.0000000000002250 |
0.328 |
|
| 2021 |
Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Tian Z, Saad F, Briganti A, Shariat SF, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 34553428 DOI: 10.1111/iju.14701 |
0.455 |
|
| 2021 |
Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, Briganti A, Terrone C, Shariat SF, Tilki D, Kluth LA, et al. Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy exposed patients. The Prostate. PMID 34523162 DOI: 10.1002/pros.24235 |
0.474 |
|
| 2021 |
Tombal BF, Freedland SJ, Armstrong AJ, Beer TM, Stenzl A, Sternberg CN, Hussain M, Ganguli A, Ramaswamy K, Bhadauria H, Ivanescu C, Turnbull J, Holmstrom S, Saad F. Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trials. Prostate Cancer and Prostatic Diseases. PMID 34518652 DOI: 10.1038/s41391-021-00447-9 |
0.384 |
|
| 2021 |
Mehra C, Chung JH, He Y, Lara-Márquez M, Goyette MA, Boufaied N, Barrès V, Ouellet V, Guérard KP, Delliaux C, Saad F, Lapointe J, Côté JF, Labbé DP, Lamarche-Vane N. CdGAP promotes prostate cancer metastasis by regulating epithelial-to-mesenchymal transition, cell cycle progression, and apoptosis. Communications Biology. 4: 1042. PMID 34493786 DOI: 10.1038/s42003-021-02520-4 |
0.431 |
|
| 2021 |
Oudard S, Hadaschik B, Saad F, Cella D, Basch E, Graff JN, Uemura H, Dibaj S, Li S, Brookman-May SD, De Porre P, Bevans KB, Trudeau JJ, Small EJ, Smith MR. Health-related Quality of Life at the SPARTAN Final Analysis of Apalutamide for Nonmetastatic Castration-resistant Prostate Cancer Patients Receiving Androgen Deprivation Therapy. European Urology Focus. PMID 34479838 DOI: 10.1016/j.euf.2021.08.005 |
0.497 |
|
| 2021 |
Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, Saad F, Shariat SF, Montorsi F, Briganti A, Karakiewicz PI. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. World Journal of Urology. PMID 34436637 DOI: 10.1007/s00345-021-03816-0 |
0.48 |
|
| 2021 |
Lopez P, Newton RU, Taaffe DR, Singh F, Buffart LM, Spry N, Tang C, Saad F, Galvão DA. Associations of fat and muscle mass with overall survival in men with prostate cancer: a systematic review with meta-analysis. Prostate Cancer and Prostatic Diseases. PMID 34420038 DOI: 10.1038/s41391-021-00442-0 |
0.386 |
|
| 2021 |
Saad F, Shore ND. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer. Therapeutic Advances in Medical Oncology. 13: 1758835921998586. PMID 34408793 DOI: 10.1177/1758835921998586 |
0.444 |
|
| 2021 |
Wenzel M, Würnschimmel C, Nocera L, Ruvolo CC, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Roos FC, Mandel P, Chun FKH, Karakiewicz PI. The effect of primary urological cancers on survival in men with secondary prostate cancer. The Prostate. PMID 34402086 DOI: 10.1002/pros.24209 |
0.465 |
|
| 2021 |
de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, et al. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. The Lancet. Oncology. PMID 34388386 DOI: 10.1016/S1470-2045(21)00376-4 |
0.425 |
|
| 2021 |
Wenzel M, Collà Ruvolo C, Nocera L, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Graefen M, Becker A, Mandel P, Chun FKH, Karakiewicz PI. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable intermediate risk prostate cancer across United States SEER registries. Cancer Epidemiology. 74: 101994. PMID 34364187 DOI: 10.1016/j.canep.2021.101994 |
0.457 |
|
| 2021 |
Coelingh Bennink HJT, van Moorselaar JA, Crawford ED, Roos EPM, Somford DM, Roeleveld TA, de Haan TD, van Melick HHE, Reisman Y, Zimmerman Y, van Osta G, Krijgh J, Shore ND, Saad F, Schally AV, et al. Estetrol Cotreatment of Androgen Deprivation Therapy in Infiltrating or Metastatic, Castration-sensitive Prostate Cancer: A Randomized, Double-blind, Phase II Trial (PCombi). European Urology Open Science. 28: 52-61. PMID 34337526 DOI: 10.1016/j.euros.2021.04.005 |
0.44 |
|
| 2021 |
Wenzel M, Würnschimmel C, Chierigo F, Flammia RS, Tian Z, Shariat SF, Gallucci M, Terrone C, Saad F, Tilki D, Graefen M, Becker A, Kluth LA, Mandel P, Chun FKH, et al. Nomogram Predicting Downgrading in National Comprehensive Cancer Network High-risk Prostate Cancer Patients Treated with Radical Prostatectomy. European Urology Focus. PMID 34334344 DOI: 10.1016/j.euf.2021.07.008 |
0.462 |
|
| 2021 |
Wenzel M, Dariane C, Saad F, Karakiewicz PI, Mandel P, Chun FKH, Tilki D, Graefen M, Delouya G, Taussky D, Würnschimmel C. The impact of time to prostate specific antigen nadir on biochemical recurrence and mortality rates after radiation therapy for localized prostate cancer. Urologic Oncology. PMID 34325988 DOI: 10.1016/j.urolonc.2021.06.025 |
0.456 |
|
| 2021 |
Wenzel M, Würnschimmel C, Chierigo F, Tian Z, Shariat SF, Terrone C, Saad F, Tilki D, Graefen M, Roos FC, A Kluth L, Mandel P, Chun FKH, Karakiewicz PI. Assessment of the optimal number of positive biopsy cores to discriminate between cancer-specific mortality in high-risk versus very high-risk prostate cancer patients. The Prostate. PMID 34312910 DOI: 10.1002/pros.24202 |
0.424 |
|
| 2021 |
Wallis CJD, Shayegan B, Morgan SC, Hamilton RJ, Cagiannos I, Basappa NS, Ferrario C, Gotto GT, Fernandes R, Roy S, Noonan KL, Niazi T, Hotte SJ, Saad F, Hew H, et al. Prognostic Association between Common Laboratory Tests and Overall Survival in Elderly Men with De Novo Metastatic Castration Sensitive Prostate Cancer: A Population-Based Study in Canada. Cancers. 13. PMID 34200349 DOI: 10.3390/cancers13112844 |
0.382 |
|
| 2021 |
Wenzel M, Würnschimmel C, Ruvolo CC, Nocera L, Tian Z, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. The Prostate. PMID 34184780 DOI: 10.1002/pros.24184 |
0.403 |
|
| 2021 |
Finelli A, Beer TM, Chowdhury S, Evans CP, Fizazi K, Higano CS, Kim J, Martin L, Saad F, Saarela O. Comparison of Joint and Landmark Modeling for Predicting Cancer Progression in Men With Castration-Resistant Prostate Cancer: A Secondary Post Hoc Analysis of the PREVAIL Randomized Clinical Trial. Jama Network Open. 4: e2112426. PMID 34129025 DOI: 10.1001/jamanetworkopen.2021.12426 |
0.438 |
|
| 2021 |
Saad F, Hotte SJ, Finelli A, Malone S, Niazi T, Noonan K, Shayegan B, So AI, Danielson B, Basappa NS, Cagiannos I, Canil C, Delouya G, Fernandes R, Ferrario C, et al. Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 34125066 DOI: 10.5489/cuaj.7347 |
0.383 |
|
| 2021 |
Saad F, Hamilou Z, Lattouf JB. A drug safety evaluation of enzalutamide to treat advanced prostate cancer. Expert Opinion On Drug Safety. 20: 741-749. PMID 34114527 DOI: 10.1080/14740338.2021.1919620 |
0.434 |
|
| 2021 |
Feng FY, Thomas S, Saad F, Gormley M, Yu MK, Ricci DS, Rooney B, Brookman-May S, McCarthy S, Olmos D, Chowdhury S, Hadaschik B, Liu Y, Davicioni E, Smith MR, et al. Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer. Jama Oncology. PMID 34081076 DOI: 10.1001/jamaoncol.2021.1463 |
0.47 |
|
| 2021 |
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, Briganti A, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. Prostate Cancer and Prostatic Diseases. PMID 34054128 DOI: 10.1038/s41391-021-00395-4 |
0.437 |
|
| 2021 |
Dariane C, Taussky D, Delouya G, Wenzel M, Karakiewicz P, Saad F, Würnschimmel C. Validation of the new STAR-CAP prognostic group staging system in prostate cancer patients treated with radiation therapy. World Journal of Urology. 39: 4127-4133. PMID 34052878 DOI: 10.1007/s00345-021-03743-0 |
0.452 |
|
| 2021 |
Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Maurer T, Steuber T, Tilki D, Briganti A, Saad F, Chun FK, Graefen M, Karakiewicz PI. Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 34047401 DOI: 10.1111/iju.14586 |
0.485 |
|
| 2021 |
Morris MJ, Mota JM, Lacuna K, Hilden P, Gleave M, Carducci MA, Saad F, Cohn ED, Filipenko J, Heller G, Shore N, Armstrong AJ, Scher HI. Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). European Urology Oncology. PMID 34020931 DOI: 10.1016/j.euo.2021.04.008 |
0.408 |
|
| 2021 |
Wenzel M, Würnschimmel C, Chierigo F, Tian Z, Shariat SF, Terrone C, Saad F, Tilki D, Graefen M, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Non-cancer mortality in elderly prostate cancer patients treated with combination of radical prostatectomy and external beam radiation therapy. The Prostate. PMID 34010465 DOI: 10.1002/pros.24169 |
0.452 |
|
| 2021 |
Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non-metastatic castration-resistant prostate cancer. Nature Reviews. Urology. PMID 34002069 DOI: 10.1038/s41585-021-00470-4 |
0.528 |
|
| 2021 |
Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, Shariat SF, Mirone V, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 33993551 DOI: 10.1111/iju.14595 |
0.427 |
|
| 2021 |
Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, Shariat SF, Saad F, Montorsi F, Briganti A, Karakiewicz PI. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. Urologic Oncology. PMID 33992522 DOI: 10.1016/j.urolonc.2021.04.004 |
0.427 |
|
| 2021 |
Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, Shariat SF, Mandel P, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. World Journal of Urology. PMID 33978812 DOI: 10.1007/s00345-021-03720-7 |
0.492 |
|
| 2021 |
Wenzel M, Würnschimmel C, Chierigo F, Mori K, Tian Z, Terrone C, Shariat SF, Saad F, Tilki D, Graefen M, Mandel P, Roos FC, Chun FKH, Karakiewicz PI. Pattern of Biopsy Gleason Grade Group 5 (4 + 5 vs 5 + 4 vs 5 + 5) Predicts Survival After Radical Prostatectomy or External Beam Radiation Therapy. European Urology Focus. PMID 33933420 DOI: 10.1016/j.euf.2021.04.011 |
0.302 |
|
| 2021 |
Clairefond S, Ouellet V, Péant B, Barrès V, Karakiewicz PI, Mes-Masson AM, Saad F. Expression of ERBB Family Members as Predictive Markers of Prostate Cancer Progression and Mortality. Cancers. 13. PMID 33918389 DOI: 10.3390/cancers13071688 |
0.361 |
|
| 2021 |
Nocera L, Collà Ruvolo C, Stolzenbach LF, Deuker M, Tian Z, Gandaglia G, Fossati N, Abdollah F, Suardi N, Mirone V, Graefen M, Chun FK, Saad F, Montorsi F, Briganti A, et al. Improving the stratification of intermediate risk prostate cancer. Minerva Urology and Nephrology. PMID 33887893 DOI: 10.23736/S2724-6051.21.04314-7 |
0.457 |
|
| 2021 |
Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. European Urology Focus. PMID 33853754 DOI: 10.1016/j.euf.2021.04.003 |
0.469 |
|
| 2021 |
Alcaidinho A, Nguyen DD, Delouya G, Zorn KC, Saad F, Taussky D, Liberman D. The interaction between inflammation, urinary symptoms and erectile dysfunction in early-stage prostate cancer treated with brachytherapy. Andrologia. e14070. PMID 33852165 DOI: 10.1111/and.14070 |
0.335 |
|
| 2021 |
Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Graefen M, Becker A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. Clinical Genitourinary Cancer. PMID 33849813 DOI: 10.1016/j.clgc.2021.03.015 |
0.473 |
|
| 2021 |
Emond JP, Lacombe L, Caron P, Turcotte V, Simonyan D, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C, Lévesque E. Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. British Journal of Cancer. PMID 33828256 DOI: 10.1038/s41416-021-01376-z |
0.485 |
|
| 2021 |
Lounis MA, Ouellet V, Péant B, Caron C, Li Z, Al-Mass A, Madiraju SRM, Mes-Masson AM, Prentki M, Saad F. Elevated Expression of Glycerol-3-Phosphate Phosphatase as a Biomarker of Poor Prognosis and Aggressive Prostate Cancer. Cancers. 13. PMID 33805661 DOI: 10.3390/cancers13061273 |
0.493 |
|
| 2021 |
Saad F, Chi KN, Shore ND, Graff JN, Posadas EM, Lattouf JB, Espina BM, Zhu E, Yu A, Hazra A, De Meulder M, Mamidi RNVS, Bradic B, Francis P, Hayreh V, et al. Niraparib with androgen receptor-axis-targeted therapy in patients with metastatic castration-resistant prostate cancer: safety and pharmacokinetic results from a phase 1b study (BEDIVERE). Cancer Chemotherapy and Pharmacology. PMID 33754187 DOI: 10.1007/s00280-021-04249-7 |
0.466 |
|
| 2021 |
Wenzel M, Nocera L, Ruvolo CC, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 33683934 DOI: 10.1097/JU.0000000000001695 |
0.434 |
|
| 2021 |
Saad F, Bögemann M, Suzuki K, Shore N. Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. Prostate Cancer and Prostatic Diseases. 24: 323-334. PMID 33558665 DOI: 10.1038/s41391-020-00310-3 |
0.494 |
|
| 2021 |
Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, et al. 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 15: E81-E90. PMID 33556313 DOI: 10.5489/cuaj.7074 |
0.433 |
|
| 2021 |
Saad F. UPDATE - 2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) castration-resistant prostate cancer (CRPC) guideline: What has changed since 2019? Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 15: 11-12. PMID 33556308 DOI: 10.5489/cuaj.7160 |
0.445 |
|
| 2021 |
Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Briganti A, Tilki D, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Sex-Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. Clinical Genitourinary Cancer. PMID 33526327 DOI: 10.1016/j.clgc.2020.12.001 |
0.331 |
|
| 2021 |
Cirne F, Aghel N, Petropoulos JA, Klotz L, Lenihan DJ, Saad F, Pinthus J, Leong DP. THE CARDIOVASCULAR EFFECTS OF GNRH ANTAGONISTS IN MEN WITH PROSTATE CANCER. European Heart Journal. Cardiovascular Pharmacotherapy. PMID 33470403 DOI: 10.1093/ehjcvp/pvab005 |
0.422 |
|
| 2020 |
Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Comparison Between Urothelial and Non-Urothelial Urethral Cancer. Frontiers in Oncology. 10: 629692. PMID 33585257 DOI: 10.3389/fonc.2020.629692 |
0.311 |
|
| 2020 |
Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Gallina A, Montorsi F, Black P, Kassouf W, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Racial differences in the distribution of bladder cancer metastases: a population-based analysis. Central European Journal of Urology. 73: 407-415. PMID 33552564 DOI: 10.5173/ceju.2020.0269 |
0.306 |
|
| 2020 |
Fitch M, Ouellet V, Pang K, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, Loiselle C, So A, Sutcliffe S, Tanguay S, Saad F, Mes-Masson AM. Comparing Perspectives of Canadian Men Diagnosed With Prostate Cancer and Health Care Professionals About Active Surveillance. Journal of Patient Experience. 7: 1122-1129. PMID 33457554 DOI: 10.1177/2374373520932735 |
0.324 |
|
| 2020 |
Wenzel M, Deuker M, Stolzenbach F, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, Briganti A, Kluth LA, Chun FKH, Karakiewicz PI. The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. Urologic Oncology. PMID 33309509 DOI: 10.1016/j.urolonc.2020.11.031 |
0.329 |
|
| 2020 |
Stolzenbach LF, Rosiello G, Deuker M, Martin T, Knipper S, Tian Z, Briganti A, Zorn KC, Saad F, Chun FKH, Graefen M, Karakiewicz PI. External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. Urologic Oncology. PMID 33189532 DOI: 10.1016/j.urolonc.2020.10.011 |
0.479 |
|
| 2020 |
Lounis MA, Péant B, Leclerc-Desaulniers K, Ganguli D, Daneault C, Ruiz M, Zoubeidi A, Mes-Masson AM, Saad F. Modulation of de Novo Lipogenesis Improves Response to Enzalutamide Treatment in Prostate Cancer. Cancers. 12. PMID 33187317 DOI: 10.3390/cancers12113339 |
0.475 |
|
| 2020 |
Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Maurer T, Tilki D, Briganti A, Saad F, Mirone V, Chun FKH, Graefen M, Karakiewicz PI. Differences between rural and urban prostate cancer patients. World Journal of Urology. PMID 33155063 DOI: 10.1007/s00345-020-03483-7 |
0.42 |
|
| 2020 |
Stolzenbach LF, Rosiello G, Pecoraro A, Palumbo C, Luzzago S, Deuker M, Tian Z, Knipper AS, Pompe R, Zorn KC, Shariat SF, Chun FKH, Graefen M, Saad F, Karakiewicz PI. Prostate Cancer Grade and Stage Misclassification in Active Surveillance Candidates: Black Versus White Patients. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 1492-1499. PMID 33152695 DOI: 10.6004/jnccn.2020.7580 |
0.417 |
|
| 2020 |
Clairefond S, Péant B, Ouellet V, Barrès V, Tian Z, Trudel D, Karakiewicz PI, Mes-Masson AM, Saad F. PUMA and NOXA Expression in Tumor-Associated Benign Prostatic Epithelial Cells Are Predictive of Prostate Cancer Biochemical Recurrence. Cancers. 12. PMID 33138186 DOI: 10.3390/cancers12113187 |
0.465 |
|
| 2020 |
Hussain M, Lin D, Saad F, Vapiwala N, Chapin BF, Sandler H, Evans CP, Carducci MA, Sachdev S. Newly Diagnosed High-Risk Prostate Cancer in an Era of Rapidly Evolving New Imaging: How Do We Treat? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2002268. PMID 33048621 DOI: 10.1200/JCO.20.02268 |
0.431 |
|
| 2020 |
Rosiello G, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. Urologic Oncology. PMID 33036900 DOI: 10.1016/j.urolonc.2020.09.004 |
0.307 |
|
| 2020 |
Saad F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Lin X, Sugg J, Steinberg J, Noerby B, Shore ND, Hussain M. Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. European Urology. PMID 33010985 DOI: 10.1016/j.eururo.2020.08.025 |
0.471 |
|
| 2020 |
Parker CC, Clarke NW, Cook AD, Kynaston HG, Petersen PM, Catton C, Cross W, Logue J, Parulekar W, Payne H, Persad R, Pickering H, Saad F, Anderson J, Bahl A, et al. Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet (London, England). PMID 33002429 DOI: 10.1016/S0140-6736(20)31553-1 |
0.417 |
|
| 2020 |
Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, Montorsi F, Shariat SF, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. Primary lymphomas of the genitourinary tract: A population-based study. Asian Journal of Urology. 7: 332-339. PMID 32995277 DOI: 10.1016/J.Ajur.2019.11.002 |
0.392 |
|
| 2020 |
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, Özgüroğlu M, Kang J, et al. Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine. PMID 32955174 DOI: 10.1056/Nejmoa2022485 |
0.544 |
|
| 2020 |
Collà Ruvolo C, Stolzenbach LF, Nocera L, Deuker M, Mistretta FA, Luzzago S, Tian Z, Longo N, Graefen M, Chun FKH, Saad F, Briganti A, De Cobelli O, Mirone V, Karakiewicz PI. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. Urologic Oncology. PMID 32950397 DOI: 10.1016/J.Urolonc.2020.08.012 |
0.522 |
|
| 2020 |
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Brookman-May SD, Li S, Zhang K, et al. Apalutamide and Overall Survival in Prostate Cancer. European Urology. PMID 32907777 DOI: 10.1016/J.Eururo.2020.08.011 |
0.578 |
|
| 2020 |
Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Mansour M, Tian Z, Tilki D, Steuber T, Briganti A, Saad F, Chun FKH, Graefen M, Karakiewicz PI. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. Prostate Cancer and Prostatic Diseases. PMID 32873918 DOI: 10.1038/S41391-020-00276-2 |
0.507 |
|
| 2020 |
Kucharczyk MJ, So J, Gravis G, Sweeney C, Saad F, Niazi T. A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 32858066 DOI: 10.1016/J.Radonc.2020.08.011 |
0.546 |
|
| 2020 |
Hotte SJ, Finelli A, Chi KN, Canil C, Fleshner N, Kapoor A, Kolinsky M, Malone S, Morash C, Niazi T, Noonan KL, Ong M, Pouliot F, Shayegan B, So AI, ... ... Saad F, et al. Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 32853135 DOI: 10.5489/Cuaj.6779 |
0.549 |
|
| 2020 |
Grosset AA, Dallaire F, Nguyen T, Birlea M, Wong J, Daoust F, Roy N, Kougioumoutzakis A, Azzi F, Aubertin K, Kadoury S, Latour M, Albadine R, Prendeville S, Boutros P, ... ... Saad F, et al. Identification of intraductal carcinoma of the prostate on tissue specimens using Raman micro-spectroscopy: A diagnostic accuracy case-control study with multicohort validation. Plos Medicine. 17: e1003281. PMID 32797086 DOI: 10.1371/Journal.Pmed.1003281 |
0.51 |
|
| 2020 |
Deuker M, Martin T, Stolzenbach F, Rosiello G, Collà Ruvolo C, Nocera L, Tian Z, Becker A, Kluth L, Roos FC, Tilki D, Shariat SF, Black PC, Kassouf W, Saad F, et al. Bladder Cancer: A Comparison Between Non-urothelial Variant Histology and Urothelial Carcinoma Across All Stages and Treatment Modalities. Clinical Genitourinary Cancer. PMID 32782133 DOI: 10.1016/J.Clgc.2020.07.011 |
0.389 |
|
| 2020 |
Alcaidinho A, Delouya G, Bahary J, Saad F, Taussky D. Active surveillance before radiotherapy - outcome and predictive factors for multiple biopsies before treatment. Cuaj-Canadian Urological Association Journal. 15. PMID 32701446 DOI: 10.5489/Cuaj.6523 |
0.439 |
|
| 2020 |
Palumbo C, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, Shariat SF, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Bladder cancer incidence rates and trends in young adults aged 20-39 years. Urologic Oncology. 38: 934.e11-934.e19. PMID 32653412 DOI: 10.1016/J.Urolonc.2020.06.009 |
0.322 |
|
| 2020 |
Malaquin N, Vancayseele A, Gilbert S, Antenor-Habazac L, Olivier MA, Ait Ali Brahem Z, Saad F, Delouya G, Rodier F. DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. Cells. 9. PMID 32630281 DOI: 10.3390/Cells9071593 |
0.422 |
|
| 2020 |
Taussky D, Delouya G, Lambert C, Bahary JP, Saad F. The relationship between pre-radiation therapy testosterone levels and prostate cancer aggressiveness. Andrologia. e13731. PMID 32628305 DOI: 10.1111/And.13731 |
0.5 |
|
| 2020 |
Armstrong AJ, Lin P, Tombal B, Saad F, Higano CS, Joshua AM, Parli T, Rosbrook B, van Os S, Beer TM. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. European Urology. PMID 32527692 DOI: 10.1016/J.Eururo.2020.04.061 |
0.563 |
|
| 2020 |
Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, Zohren F, Lin X, Modelska K, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. The New England Journal of Medicine. PMID 32469184 DOI: 10.1056/Nejmoa2003892 |
0.577 |
|
| 2020 |
Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. The New England Journal of Medicine. PMID 32469183 DOI: 10.1056/Nejmoa2004325 |
0.479 |
|
| 2020 |
Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. American Journal of Clinical Oncology. PMID 32467527 DOI: 10.1097/Coc.0000000000000704 |
0.393 |
|
| 2020 |
Deuker M, Stolzenbach LF, Pecoraro A, Rosiello G, Luzzago S, Tian Z, Saad F, Chun FK, Karakiewicz PI. PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions. World Journal of Urology. PMID 32458094 DOI: 10.1007/S00345-020-03242-8 |
0.481 |
|
| 2020 |
Deuker M, Franziska Stolzenbach L, Rosiello G, Luzzago S, Martin T, Tian Z, Tilki D, Shariat SF, Saad F, Kassouf W, Black PC, Chun FKH, Karakiewicz PI. Radical cystectomy improves survival in patients with stage T1 squamous cell carcinoma and neuroendocrine carcinoma of the urinary bladder. European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology. PMID 32457017 DOI: 10.1016/J.Ejso.2020.05.006 |
0.364 |
|
| 2020 |
Kassouf W, Aprikian A, Saad F, Fleshner N, Alimohamed N, Breau RH, Brimo F, Chin J, Chung P, Cornacchia T, Devins F, Eapen L, Eigl B, Fairey A, Guttman D, et al. Continuing towards optimization of bladder cancer care in Canada: Summary of the third Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 14: E115-E125. PMID 32453694 DOI: 10.5489/Cuaj.6378 |
0.365 |
|
| 2020 |
Herberts C, Murtha AJ, Fu S, Wang G, Schönlau E, Xue H, Lin D, Gleave A, Yip S, Angeles A, Hotte S, Tran B, North S, Taavitsainen S, Beja K, ... ... Saad F, et al. Activating AKT1 and PIK3CA Mutations in Metastatic Castration-Resistant Prostate Cancer. European Urology. PMID 32451180 DOI: 10.1016/J.Eururo.2020.04.058 |
0.482 |
|
| 2020 |
Shore N, Higano CS, George DJ, Sternberg CN, Saad F, Tombal B, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor O. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. Prostate Cancer and Prostatic Diseases. PMID 32404868 DOI: 10.1038/S41391-020-0236-0 |
0.547 |
|
| 2020 |
Stolzenbach LF, Rosiello G, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Tilki D, Briganti A, Saad F, Chun FKH, Graefen M, Karakiewicz PI. The Impact of Race and Age on Distribution of Metastases in Patients with Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32396050 DOI: 10.1097/Ju.0000000000001131 |
0.531 |
|
| 2020 |
Posadas EM, Chi KN, de Wit R, de Jonge MJA, Attard G, Friedlander TW, Yu MK, Hellemans P, Chien C, Abrams C, Jiao JJ, Saad F. Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase 1b Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32366670 DOI: 10.1158/1078-0432.Ccr-19-3402 |
0.572 |
|
| 2020 |
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, et al. Olaparib for Metastatic Castration-Resistant Prostate Cancer. The New England Journal of Medicine. PMID 32343890 DOI: 10.1056/Nejmoa1911440 |
0.529 |
|
| 2020 |
Beaulieu E, Laurence A, Birlea M, Sheehy G, Angulo-Rodriguez L, Latour M, Albadine R, Saad F, Trudel D, Leblond F. Wide-field optical spectroscopy system integrating reflectance and spatial frequency domain imaging to measure attenuation-corrected intrinsic tissue fluorescence in radical prostatectomy specimens. Biomedical Optics Express. 11: 2052-2072. PMID 32341866 DOI: 10.1364/Boe.388482 |
0.376 |
|
| 2020 |
Stenzl A, Dunshee C, De Giorgi U, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal B, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Effect of Enzalutamide plus Androgen Deprivation Therapy on Health-related Quality of Life in Patients with Metastatic Hormone-sensitive Prostate Cancer: An Analysis of the ARCHES Randomised, Placebo-controlled, Phase 3 Study. European Urology. PMID 32336645 DOI: 10.1016/J.Eururo.2020.03.019 |
0.56 |
|
| 2020 |
Dearnaley DP, Saltzstein DR, Sylvester JE, Karsh L, Mehlhaff BA, Pieczonka C, Bailen JL, Shi H, Ye Z, Faessel HM, Lin H, Zhu Y, Saad F, MacLean DB, Shore ND. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. European Urology. PMID 32273183 DOI: 10.1016/J.Eururo.2020.03.001 |
0.496 |
|
| 2020 |
Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, St-Hilaire PA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. World Journal of Urology. PMID 32253579 DOI: 10.1007/S00345-020-03187-Y |
0.304 |
|
| 2020 |
Shams R, Picot F, Grajales D, Sheehy G, Dallaire F, Birlea M, Saad F, Trudel D, Menard C, Leblond F, Kadoury S. Pre-clinical evaluation of an image-guided in-situ Raman spectroscopy navigation system for targeted prostate cancer interventions. International Journal of Computer Assisted Radiology and Surgery. PMID 32227280 DOI: 10.1007/S11548-020-02136-9 |
0.471 |
|
| 2020 |
Rosiello G, Palumbo C, Knipper S, Deuker M, Stolzenbach LF, Tian Z, Gandaglia G, Fossati N, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. Prostate Cancer and Prostatic Diseases. PMID 32203071 DOI: 10.1038/s41391-020-0225-3 |
0.339 |
|
| 2020 |
Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. Journal of Endourology. 34: 600-607. PMID 32178532 DOI: 10.1089/End.2020.0074 |
0.335 |
|
| 2020 |
Mistretta FA, Negrean‐Dzyuba C, Palumbo C, Pecoraro A, Knipper S, Tian Z, Musi G, Montanari E, Perrotte P, Briganti A, Shariat SF, Saad F, Cobelli Od, Karakiewicz PI. Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. International Journal of Urology. 27: 402-407. PMID 32172530 DOI: 10.1111/Iju.14206 |
0.375 |
|
| 2020 |
Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. Urologic Oncology. PMID 32139292 DOI: 10.1016/J.Urolonc.2020.02.004 |
0.337 |
|
| 2020 |
Jamaspishvili T, Patel PG, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Kawashima A, How N, Okello JB, Guedes LB, Ouellet V, Picanço C, Koti M, Reis RB, ... Saad F, et al. Risk stratification of prostate cancer through quantitative assessment of PTEN loss (qPTEN). Journal of the National Cancer Institute. PMID 32129857 DOI: 10.1093/Jnci/Djaa032 |
0.518 |
|
| 2020 |
Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Deuker M, Mistretta FA, Tian Z, Fossati N, Gallina A, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. Journal of Surgical Oncology. PMID 32107785 DOI: 10.1002/Jso.25877 |
0.415 |
|
| 2020 |
Saad F, Fleshner N, Pickles T, Niazi T, Lukka H, Pouliot F, Martins I, Klotz L. Testosterone Breakthrough Rates during Androgen Deprivation Therapy for Castration Sensitive Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 32096678 DOI: 10.1097/Ju.0000000000000809 |
0.524 |
|
| 2020 |
George DJ, Sartor O, Miller K, Saad F, Tombal B, Kalinovský J, Jiao X, Tangirala K, Sternberg CN, Higano CS. Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States. Clinical Genitourinary Cancer. PMID 32057714 DOI: 10.1016/J.Clgc.2019.12.019 |
0.495 |
|
| 2020 |
Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Deuker M, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Karakiewicz PI. The effect of age on cancer-specific mortality in patients with prostate cancer: a population-based study across all stages. Cancer Causes & Control : Ccc. PMID 32034540 DOI: 10.1007/s10552-020-01273-5 |
0.47 |
|
| 2020 |
Gillessen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, Briganti A, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, ... ... Saad F, et al. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. European Urology. PMID 32001144 DOI: 10.1016/J.Eururo.2020.01.012 |
0.56 |
|
| 2020 |
So AI, Chi KN, Danielson B, Fleshner NE, Kapoor A, Niazi T, Pouliot F, Rendon RA, Shayegan B, Sridhar S, Vigneault E, Saad F. Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 14: 17-23. PMID 31999544 DOI: 10.5489/Cuaj.6384 |
0.551 |
|
| 2020 |
Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. World Journal of Urology. PMID 31960108 DOI: 10.1007/S00345-020-03083-5 |
0.404 |
|
| 2020 |
Sternberg CN, Saad F, Graff JN, Peer A, Vaishampayan UN, Leung E, Rosenbaum E, Gurney H, Epstein RJ, Davis ID, Wu B, Trandafir L, Wagner VJ, Hussain M. A randomised phase II trial of three dosing regimens of radium-223 in patients with bone metastatic castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 31: 257-265. PMID 31959342 DOI: 10.1016/J.Annonc.2019.10.025 |
0.553 |
|
| 2020 |
Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy Journal of the National Comprehensive Cancer Network. 18: 44-51. PMID 31910387 DOI: 10.6004/Jnccn.2019.7350 |
0.364 |
|
| 2020 |
Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Fossati N, Shariat SF, Saad F, Montorsi F, Graefen M, Briganti A, Karakiewicz PI. Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. Prostate Cancer and Prostatic Diseases. 23: 260-268. PMID 31685982 DOI: 10.1038/S41391-019-0183-9 |
0.41 |
|
| 2020 |
Yu EY, Laidley D, Pouliot F, Probst S, Saad F, Sabbagh R, Sartor AO. A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW). Journal of Clinical Oncology. 38. DOI: 10.1200/Jco.2020.38.6_Suppl.Tps260 |
0.548 |
|
| 2020 |
Scher HI, Saad F, Mehra M, Nair S, Dearden L, Potluri RC. Impact of upstream use of novel hormonal therapy on progression of patients (pts) to metastatic castration-resistant prostate cancer (mCRPC) in the United States (US). Journal of Clinical Oncology. 38: 92-92. DOI: 10.1200/Jco.2020.38.6_Suppl.92 |
0.555 |
|
| 2020 |
Higano CS, Saad F, Sartor AO, Miller K, Conti P, George DJ, Sternberg CN, Shore ND, Sade JP, Bellmunt J, Smith MR, Logothetis C, Verholen F, Kalinovsky J, Bayh I, et al. Clinical outcomes and patient (pt) profiles in REASSURE: An observational study of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 32-32. DOI: 10.1200/Jco.2020.38.6_Suppl.32 |
0.453 |
|
| 2020 |
Hotte SJ, Finelli A, Chi KN, Canil CM, Fleshner N, Kapoor A, Kolinsky MP, Malone S, Morash C, Niazi T, Noonan K, Ong M, Pouliot F, Shayegan B, So A, ... ... Saad F, et al. Real-world management of advanced prostate cancer: A Canadian comparison of academic specialists and community-based prostate cancer physicians. Journal of Clinical Oncology. 38: 29-29. DOI: 10.1200/Jco.2020.38.6_Suppl.29 |
0.548 |
|
| 2020 |
Hussain MHA, Mateo J, Sandhu SK, Fizazi K, Saad F, Shore ND, Olmos D, Corcoran C, Sibilla C, Kohlmann A, Adelman CA, Elvin JA, Goessl CD, Burgents J, De Bono JS. Next-generation sequencing (NGS) of tumor tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC): The PROfound phase III study experience. Journal of Clinical Oncology. 38: 195-195. DOI: 10.1200/Jco.2020.38.6_Suppl.195 |
0.359 |
|
| 2020 |
Bono JSD, Fizazi K, Saad F, Shore ND, Roubaud G, Ozguroglu M, Penel N, Matsubara N, Mehra N, Procopio G, Kolinsky MP, Nishimura K, Feyerabend S, Joung JY, Vogelzang NJ, et al. PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations. Journal of Clinical Oncology. 38: 134-134. DOI: 10.1200/Jco.2020.38.6_Suppl.134 |
0.519 |
|
| 2020 |
Saad F, Chi KN, Shore ND, Graff JN, Posadas EM, Espina BM, Zhu E, Hazra A, Bradic B, Cheng S, Hayreh V, Rezazadeh A. Phase Ib study of niraparib plus androgen receptor-targeted therapy (ART) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 122-122. DOI: 10.1200/Jco.2020.38.6_Suppl.122 |
0.478 |
|
| 2020 |
Bono JSD, Mehra N, Higano CS, Saad F, Buttigliero C, Mata M, Chen H, Healy CG, Paccagnella ML, Czibere A, Fizazi K. TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC)—First interim analysis (IA). Journal of Clinical Oncology. 38: 119-119. DOI: 10.1200/Jco.2020.38.6_Suppl.119 |
0.467 |
|
| 2020 |
Smith MR, Fizazi K, Sandhu SK, Kelly WK, Efstathiou E, Lara P, Yu EY, George DJ, Chi KN, Saad F, Summa J, Freedman JM, Mason G, Espina BM, Zhu E, et al. Niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD): Correlative measures of tumor response in phase II GALAHAD study. Journal of Clinical Oncology. 38: 118-118. DOI: 10.1200/Jco.2020.38.6_Suppl.118 |
0.446 |
|
| 2020 |
Shore ND, George DJ, Saad F, Cookson M, Saltzstein DR, Tutrone RF, Akaza H, Bossi A, Veenhuyzen Dv, Selby B, Fan X, Kang V, Walling JM, Tombal BF. HERO phase III trial: Results comparing relugolix, an oral GnRH receptor antagonist, versus leuprolide acetate for advanced prostate cancer. Journal of Clinical Oncology. 38: 5602-5602. DOI: 10.1200/Jco.2020.38.15_Suppl.5602 |
0.531 |
|
| 2020 |
Bono JSD, Mehra N, Higano CS, Saad F, Buttigliero C, Oort IMv, Mata M, Chen H, Healy CG, Paccagnella ML, Czibere A, Fizazi K. TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA). Journal of Clinical Oncology. 38: 5566-5566. DOI: 10.1200/Jco.2020.38.15_Suppl.5566 |
0.464 |
|
| 2020 |
Chi KN, Mukherjee S, Saad F, Winquist E, Ong M, Kolinsky MP, Sacher AG, Ferrario C, Salim M, Macfarlane RJ, Iqbal N, Hotte SJ, Annala M, Petrovic J, Tu D, et al. Prostate cancer biomarker enrichment and treatment selection (PC-BETS) study: A Canadian cancer trials group phase II umbrella trial for metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 38: 5551-5551. DOI: 10.1200/Jco.2020.38.15_Suppl.5551 |
0.534 |
|
| 2020 |
Higano CS, Harshman LC, Dizdarevic S, Logue J, Richardson T, George S, Song D, Jong IJd, Tomaszewski J, Saad F, Miller K, Meltzer J, Sandstrom P, Tombal BF, Sartor AO. Safety and overall survival (OS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) plus subsequent taxane therapy. Journal of Clinical Oncology. 38: 5542-5542. DOI: 10.1200/Jco.2020.38.15_Suppl.5542 |
0.528 |
|
| 2020 |
Chi KN, Saad F, Chowdhury S, Graff JN, Agarwal N, Oudard S, Li G, Lopez-Gitlitz A, Larsen JS, McCarthy SA, Mundle S, Smith MR, Small EJ. Prostate-specific antigen (PSA) kinetics in patients (pts) with advanced prostate cancer treated with apalutamide: Results from the TITAN and SPARTAN studies. Journal of Clinical Oncology. 38: 5541-5541. DOI: 10.1200/Jco.2020.38.15_Suppl.5541 |
0.493 |
|
| 2020 |
Thiery-Vuillemin A, De Bono JS, Saad F, Procopio G, Shore ND, Fizazi K, Roubaud G, Anjos Gd, Gravis G, Joung JY, Matsubara N, Castellano D, Degboe A, Gresty C, Kang J, et al. Health-related quality of life (HRQoL) for olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations: PROfound. Journal of Clinical Oncology. 38: 5539-5539. DOI: 10.1200/Jco.2020.38.15_Suppl.5539 |
0.51 |
|
| 2020 |
Saad F, Roubaud G, Procopio G, Shore ND, Fizazi K, Thiery-Vuillemin A, Anjos Gd, Gravis G, Joung JY, Matsubara N, Castellano D, Hussain MHA, Degboe A, Gresty C, Kang J, et al. Impact of olaparib vs physician’s choice of new hormonal agent (pcNHA) on burden of pain in metastatic castration-resistant prostate cancer (mCRPC): PROfound. Journal of Clinical Oncology. 38: 5538-5538. DOI: 10.1200/Jco.2020.38.15_Suppl.5538 |
0.305 |
|
| 2020 |
Saad F, Graff JN, Hadaschik BA, Oudard S, Mainwaring PN, Bhaumik A, Gormley M, Londhe A, Thomas S, Lopez-Gitlitz A, Mundle S, Davicioni E, Small EJ, Smith MR, Feng FY. Molecular determinants of prostate specific antigen (PSA) kinetics and clinical response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in SPARTAN. Journal of Clinical Oncology. 38: 5521-5521. DOI: 10.1200/Jco.2020.38.15_Suppl.5521 |
0.552 |
|
| 2020 |
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith A, Brookman-May SD, Li S, Zhang K, et al. Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology. 38: 5516-5516. DOI: 10.1200/Jco.2020.38.15_Suppl.5516 |
0.443 |
|
| 2020 |
Sternberg CN, Fizazi K, Saad F, Shore ND, Giorgi UD, Penson DF, Ferreira U, Ivashchenko P, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DI, Noerby B, Zohren F, Lin X, et al. Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology. 38: 5515-5515. DOI: 10.1200/Jco.2020.38.15_Suppl.5515 |
0.537 |
|
| 2020 |
Pecoraro A, Knipper S, Palumbo C, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, Shariat SF, Saad F, Briganti A, Fiori C, Porpiglia F, Karakiewicz PI. Mp21-04 The Effect Of Age On Cancer-Specific Mortality In T1A Stage Renal Cell Carcinoma Patients Across All Treatment’S Modalities: A Seer-Based Study The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000854.04 |
0.348 |
|
| 2020 |
Leyh-Bannurah S, Wolffgang U, Schmitz J, Ouellet V, Azzi F, Tian Z, Helmke B, Graefen M, Budäus L, Karakiewicz PI, Trudel D, Saad F. Mp19-20 State-Of-The-Art Weakly Supervised Automated Classification Of Prostate Cancer Tissue Microarrays Via Deep Learning: Can Sufficient Accuracy Be Achieved Without Manual Patch Level Annotation? The Journal of Urology. 203. DOI: 10.1097/Ju.0000000000000852.020 |
0.437 |
|
| 2019 |
Palumbo C, Mazzone E, Mistretta FA, Knipper S, Perrotte P, Shariat SF, Saad F, Kapoor A, Lattouf JB, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. Clinical Genitourinary Cancer. PMID 32482565 DOI: 10.1016/J.Clgc.2019.11.010 |
0.355 |
|
| 2019 |
Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Nazzani S, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. Clinical Genitourinary Cancer. PMID 32146153 DOI: 10.1016/J.Clgc.2019.12.001 |
0.36 |
|
| 2019 |
Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. Clinical Genitourinary Cancer. PMID 32035800 DOI: 10.1016/J.Clgc.2019.10.016 |
0.413 |
|
| 2019 |
Mistretta FA, Cyr SJ, Luzzago S, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, Briganti A, Shariat SF, de Cobelli O, Karakiewicz PI. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. Clinical Genitourinary Cancer. PMID 32001182 DOI: 10.1016/J.Clgc.2019.09.008 |
0.324 |
|
| 2019 |
Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF, Marchioni M, Tian Z, Saad F, Taussky D, Briganti A, Huland H, Graefen M, Tilki D, Karakiewicz PI. Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 31793866 DOI: 10.5489/Cuaj.6087 |
0.533 |
|
| 2019 |
Rosiello G, Palumbo C, Knipper S, Pecoraro A, Dzyuba-Negrean C, Luzzago S, Tian Z, Gallina A, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. Urologic Oncology. PMID 31761614 DOI: 10.1016/j.urolonc.2019.10.018 |
0.342 |
|
| 2019 |
Feyerabend S, Saad F, Perualila NJ, Sanden SV, Diels J, Ito T, Porre PD, Fizazi K. Adjusting Overall Survival Estimates for Treatment Switching in Metastatic, Castration-Sensitive Prostate Cancer: Results from the LATITUDE Study. Targeted Oncology. 14: 681-688. PMID 31754962 DOI: 10.1007/S11523-019-00685-X |
0.467 |
|
| 2019 |
Narayan V, Harrison M, Cheng H, Kenfield S, Aggarwal R, Kwon D, McKay R, Hauger R, Hart N, Conzen S, Borno H, Jim H, Dicker A, Dorff T, Moslehi J, ... ... Saad F, et al. Improving research for prostate cancer survivorship: A statement from the Survivorship Research in Prostate Cancer (SuRECaP) working group. Urologic Oncology. PMID 31734020 DOI: 10.1016/J.Urolonc.2019.10.006 |
0.56 |
|
| 2019 |
Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Tian Z, Gandaglia G, Gallina A, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. Clinical Genitourinary Cancer. PMID 31711842 DOI: 10.1016/j.clgc.2019.10.012 |
0.471 |
|
| 2019 |
Mistretta FA, Cyr SJ, Palumbo C, Mazzone E, Knipper S, Tian Z, Nazzani S, Montanari E, Tilki D, Briganti A, Shariat SF, Perrotte P, Saad F, de Cobelli O, Karakiewicz PI. Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2-3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes. Clinical Oncology (Royal College of Radiologists (Great Britain)). PMID 31706712 DOI: 10.1016/J.Clon.2019.10.001 |
0.326 |
|
| 2019 |
Saad F, Canil C, Finelli A, Hotte SJ, Malone S, Shayegan B, So AI, Aaron L, Basappa NS, Conter HJ, Danielson B, Gotto G, Hamilton RJ, Izard JP, Kapoor A, et al. A Canadian consensus forum on the management of patients with advanced prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 31702544 DOI: 10.5489/Cuaj.6082 |
0.482 |
|
| 2019 |
Deuker M, Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, Saad F, Chun F, Karakiewicz PI. Prostate cancer characteristics and cancer-specific mortality of Native American patients. Prostate Cancer and Prostatic Diseases. PMID 31695139 DOI: 10.1038/S41391-019-0184-8 |
0.53 |
|
| 2019 |
Mazzone E, Knipper S, Mistretta FA, Palumbo C, Tian Z, Gallina A, Tilki D, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz PI. Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies Journal of the National Comprehensive Cancer Network. 17: 1344-1352. PMID 31693981 DOI: 10.6004/Jnccn.2019.7319 |
0.351 |
|
| 2019 |
Knipper S, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis. Urologic Oncology. PMID 31653563 DOI: 10.1016/j.urolonc.2019.09.015 |
0.41 |
|
| 2019 |
Saad F, Aprikian A, Finelli A, Fleshner NE, Gleave M, Kapoor A, Niazi T, North SA, Pouliot F, Rendon RA, Shayegan B, Sridhar SS, So A, Usmani N, Vigneault E, et al. 2019 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 13: 307-314. PMID 31603409 DOI: 10.5489/Cuaj.6136 |
0.586 |
|
| 2019 |
Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Tian Z, Shariat SF, Saad F, de Cobelli O, Karakiewicz PI. The effect of radical cystectomy on survival in patients with metastatic urothelial carcinoma of the urinary bladder. Journal of Surgical Oncology. PMID 31562831 DOI: 10.1002/Jso.25717 |
0.346 |
|
| 2019 |
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, De Porre P, Smith AA, Zhang K, Lopez-Gitlitz A, Smith MR. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 31560066 DOI: 10.1093/Annonc/Mdz397 |
0.552 |
|
| 2019 |
Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. International Urology and Nephrology. PMID 31542882 DOI: 10.1007/S11255-019-02284-1 |
0.538 |
|
| 2019 |
Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono JS. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. European Urology. PMID 31542304 DOI: 10.1016/J.Eururo.2019.08.034 |
0.464 |
|
| 2019 |
Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. Clinical Genitourinary Cancer. PMID 31515197 DOI: 10.1016/J.Clgc.2019.08.009 |
0.342 |
|
| 2019 |
Fendler WP, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, et al. Prostate-Specific Membrane Antigen Ligand Positron-Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31511295 DOI: 10.1158/1078-0432.Ccr-19-1050 |
0.537 |
|
| 2019 |
Mohammad AH, Assadian S, Couture F, Lefebvre KJ, El-Assaad W, Barrès V, Ouellet V, Boulay PL, Yang J, Latour M, Furic L, Muller W, Sonenberg N, Mes-Masson AM, Saad F, et al. V-ATPase-associated prorenin receptor is upregulated in prostate cancer after PTEN loss. Oncotarget. 10: 4923-4936. PMID 31452834 DOI: 10.18632/Oncotarget.27075 |
0.409 |
|
| 2019 |
Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, Briganti A, Saad F, Tilki D, Graefen M, Karakiewicz PI. A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. Clinical Genitourinary Cancer. PMID 31416752 DOI: 10.1016/j.clgc.2019.07.008 |
0.464 |
|
| 2019 |
Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, Briganti A, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. European Urology Oncology. PMID 31411975 DOI: 10.1016/J.Euo.2019.03.003 |
0.535 |
|
| 2019 |
Preisser F, Nazzani S, Mazzone E, Marchioni M, Bandini M, Tian Z, Haese A, Saad F, Zorn K, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI. Comparison of Open Versus Robotically Assisted Cytoreductive Radical Prostatectomy for Metastatic Prostate Cancer. Clinical Genitourinary Cancer. PMID 31375352 DOI: 10.1016/J.Clgc.2019.05.022 |
0.462 |
|
| 2019 |
Palumbo C, Pecoraro A, Knipper S, Rosiello G, Tian Z, Shariat SF, Simeone C, Briganti A, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. Anticancer Research. 39: 4357-4361. PMID 31366530 DOI: 10.21873/Anticanres.13604 |
0.316 |
|
| 2019 |
Danielson B, Saad F, So A, Morgan S, Hamilton RJ, Malone S, Park-Wyllie L, Zardan A, Shayegan B. Management algorithms for prostate-specific antigen progression in prostate cancer: Biochemical recurrence after definitive therapy and progression to non-metastatic castrate-resistant prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 31364976 DOI: 10.5489/Cuaj.5600 |
0.576 |
|
| 2019 |
Gómez Rivas J, Carrion DM, Alvarez-Maestro M, Cathelineau X, Sanchez-Salas R, Di Lorenzo G, Di Maio M, Paul A, Martinez-Piñeiro L, Sartor O, Saad F, Debruyne F. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand? Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology. PMID 31353876 DOI: 10.23736/S0393-2249.19.03420-9 |
0.479 |
|
| 2019 |
Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Tian Z, Shariat SF, Saad F, Briganti A, Fiori C, Porpiglia F, Karakiewicz PI. In Non-Metastatic pT1b Kidney Cancer Patients Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy. The Journal of Urology. 101097JU000000000000. PMID 31347950 DOI: 10.1097/Ju.0000000000000460 |
0.402 |
|
| 2019 |
Saad F. Continuing to Improve Outcomes of Men With Metastatic Prostate Cancer Nature Reviews Clinical Oncology. 16: 597-598. PMID 31312041 DOI: 10.1038/S41571-019-0254-9 |
0.562 |
|
| 2019 |
Saad F, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Nilsson S, Miller K, Wirth M, Reeves J, Seger M, Carles J, Heidenreich A. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program. Clinical Genitourinary Cancer. PMID 31311763 DOI: 10.1016/J.Clgc.2019.05.012 |
0.525 |
|
| 2019 |
Mistretta FA, Palumbo C, Knipper S, Mazzone E, Pecoraro A, Tian Z, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, Briganti A, de Cobelli O, Karakiewicz PI. Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. World Journal of Urology. PMID 31297629 DOI: 10.1007/S00345-019-02869-6 |
0.38 |
|
| 2019 |
Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, Briganti A, Antonelli A, Karakiewicz PI. How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. Urologic Oncology. PMID 31296422 DOI: 10.1016/J.Urolonc.2019.05.020 |
0.395 |
|
| 2019 |
Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Karakiewicz P, Lacombe L, ... ... Saad F, et al. Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network. Plos Medicine. 16: e1002847. PMID 31265453 DOI: 10.1371/Journal.Pmed.1002847 |
0.555 |
|
| 2019 |
Dankner M, Ouellet V, Communal L, Schmitt E, Perkins D, Annis MG, Barrès V, Caron C, Mes-Masson AM, Saad F, Siegel PM. CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis. The American Journal of Pathology. PMID 31202437 DOI: 10.1016/J.Ajpath.2019.04.006 |
0.497 |
|
| 2019 |
Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Lattouf JB, Musi G, Perrotte P, Montanari E, Shariat SF, Montorsi F, Saad F, de Cobelli O, Karakiewicz PI. Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. Clinical Genitourinary Cancer. PMID 31182339 DOI: 10.1016/J.Clgc.2019.04.015 |
0.346 |
|
| 2019 |
Mazzone E, Mistretta FA, Knipper S, Palumbo C, Tian Z, Pecoraro A, Preisser F, Gallina A, Shariat SF, Saad F, Graefen M, Montorsi F, Briganti A, Karakiewicz PI. Long-Term Incidence of Secondary Bladder, Rectal Cancer in Patients Treated with Brachytherapy for Localized Prostate Cancer: A Large-Scale Population-Based Analysis. Bju International. PMID 31144770 DOI: 10.1111/Bju.14841 |
0.504 |
|
| 2019 |
Knipper S, Tilki D, Mazzone E, Mistretta FA, Palumbo C, Pecoraro A, Tian Z, Briganti A, Saad F, Graefen M, Karakiewicz PI. Contemporary clinicopathological characteristics of pT0 prostate cancer at radical prostatectomy: A population-based study. Urologic Oncology-Seminars and Original Investigations. 37: 696-701. PMID 31129038 DOI: 10.1016/J.Urolonc.2019.05.001 |
0.466 |
|
| 2019 |
Slovin SF, Hussain S, Saad F, Garcia JA, Picus J, Ferraldeschi R, Crespo M, Flohr PR, Riisnaes R, Lin C, Keer H, Oganesian A, Workman P, de Bono JS. Pharmacodynamic and clinical results from a phase 1/2 study of the HSP90 inhibitor onalespib in combination with abiraterone acetate in prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31113841 DOI: 10.1158/1078-0432.Ccr-18-3212 |
0.443 |
|
| 2019 |
Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, Briganti A, Shariat SF, Saad F, Tilki D, Graefen M, Karakiewicz PI. Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. Urologic Oncology. PMID 31103337 DOI: 10.1016/j.urolonc.2019.04.023 |
0.476 |
|
| 2019 |
Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, Briganti A, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. Clinical Genitourinary Cancer. PMID 31080021 DOI: 10.1016/J.Clgc.2019.04.009 |
0.537 |
|
| 2019 |
Gaudreau PO, Clairefond S, Class CA, Boulay PL, Chrobak P, Allard B, Azzi F, Pommey S, Do KA, Saad F, Trudel D, Young M, Stagg J. WISP1 is associated to advanced disease, EMT and an inflamed tumor microenvironment in multiple solid tumors. Oncoimmunology. 8: e1581545. PMID 31069142 DOI: 10.1080/2162402X.2019.1581545 |
0.416 |
|
| 2019 |
Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So A, Park-Wyllie L, Hew H, McLeod D, Gotto G. Management algorithms for metastatic prostate cancer. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 31039111 DOI: 10.5489/Cuaj.5840 |
0.546 |
|
| 2019 |
Trinh VQ, Benzerdjeb N, Chagnon-Monarque S, Dionne N, Delouya G, Kougioumoutzakis A, Sirois J, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Zorn KC, Fradet Y, Saad F, et al. Retrospective study on the benefit of adjuvant radiotherapy in men with intraductal carcinoma of prostate. Radiation Oncology (London, England). 14: 60. PMID 31018850 DOI: 10.1186/S13014-019-1267-3 |
0.537 |
|
| 2019 |
Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. Clinical Genitourinary Cancer. PMID 31005472 DOI: 10.1016/J.Clgc.2019.03.003 |
0.314 |
|
| 2019 |
Palumbo C, Cyr SJ, Mazzone E, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, Briganti A, Kapoor A, Antonelli A, Karakiewicz PI. Impact of tumor size on cancer specific mortality after local tumor ablation in T1a renal cell carcinoma. Journal of Endourology. PMID 30990074 DOI: 10.1089/End.2019.0179 |
0.361 |
|
| 2019 |
Saad F. Importance of early treatment in metastatic prostate cancer: a question of life or death. Lancet Oncology. 20: 609-611. PMID 30987940 DOI: 10.1016/S1470-2045(19)30155-X |
0.511 |
|
| 2019 |
Jamaspishvili T, Patel P, Niu Y, Vidotto T, Caven I, Livergant R, Fu W, Ouellet V, Picanço C, Koti M, How N, Saad F, Mes-Masson AM, Lotan T, Squire J, et al. MP28-02 QUANTITATIVE MEASUREMENT OF PTEN LOSS IMPROVES RISK ASSESSMENT IN PROSTATE CANCER. The Journal of Urology. 201: e403. PMID 30950708 DOI: 10.1097/01.Ju.0000555707.15264.F6 |
0.541 |
|
| 2019 |
Saad F, Shore N, Zhang T, Sharma S, Cho HK, Jacobs IA. Emerging therapeutic targets for patients with advanced prostate cancer. Cancer Treatment Reviews. 76: 1-9. PMID 30913454 DOI: 10.1016/J.Ctrv.2019.03.002 |
0.569 |
|
| 2019 |
Gulley JL, Borre M, Vogelzang NJ, Ng S, Agarwal N, Parker CC, Pook DW, Rathenborg P, Flaig TW, Carles J, Saad F, Shore ND, Chen L, Heery CR, Gerritsen WR, et al. Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1802031. PMID 30817251 DOI: 10.1200/Jco.18.02031 |
0.526 |
|
| 2019 |
Mistretta FA, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, Briganti A, Shariat SF, de Cobelli O, Karakiewicz PI. Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. Cancer Epidemiology. 59: 135-142. PMID 30771698 DOI: 10.1016/J.Canep.2019.02.002 |
0.347 |
|
| 2019 |
Tombal B, Saad F, Penson D, Hussain M, Sternberg CN, Morlock R, Ramaswamy K, Ivanescu C, Attard G. Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. Oncology. PMID 30770294 DOI: 10.1016/S1470-2045(18)30898-2 |
0.558 |
|
| 2019 |
Wissing MD, Chevalier S, O'Flaherty A, McKercher G, Aprikian S, Saad F, Carmel M, Lacombe L, Hamel M, Aprikian A. Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada. Psycho-Oncology. PMID 30762265 DOI: 10.1002/Pon.5031 |
0.521 |
|
| 2019 |
Mazzone E, Nazzani S, Knipper S, Tian Z, Preisser F, Gallina A, Soulières D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. Ejso. 45: 1253-1259. PMID 30755341 DOI: 10.1016/J.Ejso.2019.01.218 |
0.403 |
|
| 2019 |
de Souza P, Saad F. Bone health in prostate cancer. Expert Review of Endocrinology & Metabolism. 6: 317-321. PMID 30754104 DOI: 10.1586/eem.11.4 |
0.523 |
|
| 2019 |
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M, Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara N, Nahas WC, Nolè F, et al. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 30738780 DOI: 10.1016/S1470-2045(18)30860-X |
0.589 |
|
| 2019 |
Levesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C. A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 30733309 DOI: 10.1158/1055-9965.Epi-18-1002 |
0.547 |
|
| 2019 |
Saad F. Quality of life in men with prostate cancer Lancet Oncology. 20: 325-326. PMID 30713037 DOI: 10.1016/S1470-2045(18)30863-5 |
0.497 |
|
| 2019 |
Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F. Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections. PMID 30673630 DOI: 10.1530/Ec-18-0476 |
0.383 |
|
| 2019 |
Simeone K, Guay-Lord R, Lateef MA, Péant B, Kendall-Dupont J, Orimoto AM, Carmona E, Provencher D, Saad F, Gervais T, Mes-Masson AM. Paraffin-embedding lithography and micro-dissected tissue micro-arrays: tools for biological and pharmacological analysis of ex vivo solid tumors. Lab On a Chip. PMID 30671574 DOI: 10.1039/C8Lc00982A |
0.347 |
|
| 2019 |
Heidenreich A, Gillessen S, Heinrich D, Keizman D, O'Sullivan JM, Carles J, Wirth M, Miller K, Reeves J, Seger M, Nilsson S, Saad F. Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program Bmc Cancer. 19: 12. PMID 30612558 DOI: 10.1186/S12885-018-5203-Y |
0.498 |
|
| 2019 |
Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Wisnivesky J, Karakiewicz PI. Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis? Cancer Epidemiology. 58: 83-88. PMID 30528834 DOI: 10.1016/J.Canep.2018.11.007 |
0.413 |
|
| 2019 |
Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. Clinical Genitourinary Cancer. 17: 105. PMID 30527745 DOI: 10.1016/J.Clgc.2018.11.003 |
0.365 |
|
| 2019 |
Tosco L, Briganti A, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K. Systematic Review of Systemic Therapies and Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. European Urology. 75: 44-60. PMID 30286948 DOI: 10.1016/J.Eururo.2018.07.027 |
0.525 |
|
| 2019 |
Shore ND, Sartor AO, Sternberg CN, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, Tangirala K, Higano CS. Concurrent or layered treatment (Tx) with radium-223 (Ra-223) and enzalutamide (Enza) or abiraterone plus prednisone/prednisolone (Abi/pred): A retrospective study of real-world clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 5026-5026. DOI: 10.1200/Jco.2020.38.6_Suppl.50 |
0.391 |
|
| 2019 |
Bono JSD, Higano CS, Saad F, Miller K, Chen H, Czibere A, Healy C, Fizazi K. TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair (DDR) defects and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on greater than or equal to one novel hormonal therapy (NHT). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps342 |
0.511 |
|
| 2019 |
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, Goessl CD, Kang J, Liu S, Saad F. PROPEL: A randomized, phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37. DOI: 10.1200/Jco.2019.37.7_Suppl.Tps340 |
0.43 |
|
| 2019 |
Feng FY, Thomas S, Gormley M, Lopez-Gitlitz A, Yu MK, Cheng S, Ricci DS, Rooney OB, Mainwaring PN, Olmos D, Saad F, Chowdhury S, Hadaschik BA, Fishbane N, Davicioni E, et al. Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN trial. Journal of Clinical Oncology. 37: 42-42. DOI: 10.1200/Jco.2019.37.7_Suppl.42 |
0.441 |
|
| 2019 |
Higano CS, Sternberg CN, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, Tangirala K, Sartor AO. Treatment patterns and outcomes for metastatic castration-resistant prostate cancer (mCRPC) in a real-world setting: A retrospective study of greater than 2500 patients. Journal of Clinical Oncology. 37: 256-256. DOI: 10.1200/Jco.2019.37.7_Suppl.256 |
0.439 |
|
| 2019 |
George DJ, Sternberg CN, Sartor AO, Saad F, Tombal BF, Miller K, Kalinovsky J, Jiao X, Tangirala K, Higano CS. Clinical outcome with concurrent or layered treatment with radium-223 and abiraterone: A retrospective study of real-world experience with patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 37: 253-253. DOI: 10.1200/Jco.2019.37.7_Suppl.253 |
0.439 |
|
| 2019 |
Tombal BF, Armstrong AJ, Barrus JK, Beer TM, Chowdhury S, Evans CP, Heidenreich A, Higano CS, Kamba T, Lin P, Nikolayeva N, Sugg J, Steinberg JL, Taplin ME, Saad F. Adverse events of special interest assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. Journal of Clinical Oncology. 37: 237-237. DOI: 10.1200/Jco.2019.37.7_Suppl.237 |
0.531 |
|
| 2019 |
Clarke NW, Thiery-Vuillemin A, Wiechno PJ, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Goessl CD, Burgents J, Gresty C, Degboe A, ... Saad F, et al. Health-related quality of life (HRQoL) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with olaparib in combination with abiraterone. Journal of Clinical Oncology. 37: 234-234. DOI: 10.1200/Jco.2019.37.7_Suppl.234 |
0.375 |
|
| 2019 |
Saad F, Morlock R, Ivanescu C, Sugg J, Tombal BF. Association between urinary, bowel, and hormonal treatment-related symptoms and clinical outcomes in nonmetastatic castration-resistant prostate cancer (nmCRPC): PROSPER study. Journal of Clinical Oncology. 37: 233-233. DOI: 10.1200/Jco.2019.37.7_Suppl.233 |
0.491 |
|
| 2019 |
Ouellet V, Dankner M, Desreumaux-Communal L, Schmitt E, Perkins D, Annis MG, Barres V, Caron C, Mes-Masson A, Saad F, Siegel P. CCN3/NOV as a functional driver and prognostic biomarker of prostate cancer bone metastasis. Journal of Clinical Oncology. 37: 182-182. DOI: 10.1200/Jco.2019.37.7_Suppl.182 |
0.528 |
|
| 2019 |
Saad F, Kapoor A, Aprikian AG, Casey R, Caveen M, Reiner M, Gillesby B, Finelli A. A retrospective observational study assessing bone metastases (mets) detection and management of patients (pts) with castration-resistant prostate cancer (CRPC) in Canada. Journal of Clinical Oncology. 37: 161-161. DOI: 10.1200/Jco.2019.37.7_Suppl.161 |
0.533 |
|
| 2019 |
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Espina BM, Shu Y, Rackoff WR, Rooney OB, et al. Updated analysis of progression-free survival with first subsequent therapy (PFS2) and safety in the SPARTAN study of apalutamide (APA) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology. 37: 144-144. DOI: 10.1200/Jco.2019.37.7_Suppl.144 |
0.519 |
|
| 2019 |
Scher HI, Mccormack RT, Molina A, Smith MR, Dreicer R, Saad F, Wit RD, Fizazi K, Aftab DT, Limon A, Fleisher M, Bono JSD, Kelloff GJ, Heller G. Assessment of circulating tumor cell number as a transitional surrogate endpoint for survival in phase II trials for metastatic castration-resistant prostate cancer. Journal of Clinical Oncology. 37: 143-143. DOI: 10.1200/Jco.2019.37.7_Suppl.143 |
0.441 |
|
| 2019 |
Juergens RA, Zukotynski KA, Juneau D, Krnezich L, Simms R, Forbes J, Burak ES, Valliant J, Stafford L, Armor T, Molnar I, Saad F. A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors. Journal of Clinical Oncology. 37: TPS3152-TPS3152. DOI: 10.1200/Jco.2019.37.15_Suppl.Tps3152 |
0.316 |
|
| 2019 |
Stenzl A, Dunshee C, Giorgi UD, Alekseev B, Iguchi T, Szmulewitz RZ, Flaig TW, Tombal BF, Morlock R, Ivanescu C, Ramaswamy K, Saad F, Armstrong AJ. Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study. Journal of Clinical Oncology. 37: 5044-5044. DOI: 10.1200/Jco.2019.37.15_Suppl.5044 |
0.482 |
|
| 2019 |
Pollock YG, Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Olmos D, Mainwaring PN, Lee JY, Uemura H, Bhaumik A, Londhe A, Rooney OB, Lopez-Gitlitz A, Mundle S, et al. Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT). Journal of Clinical Oncology. 37: 5025-5025. DOI: 10.1200/Jco.2019.37.15_Suppl.5025 |
0.522 |
|
| 2019 |
Graff JN, Smith MR, Saad F, Hadaschik BA, Uemura H, Lee JY, Mainwaring PN, Olmos D, Oudard S, Londhe A, Bhaumik A, Rooney OB, Lopez-Gitlitz A, Small EJ. Age-related efficacy and safety of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in subgroups of patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Post hoc analysis of SPARTAN Journal of Clinical Oncology. 37: 5024-5024. DOI: 10.1200/Jco.2019.37.15_Suppl.5024 |
0.512 |
|
| 2019 |
Small EJ, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Londhe A, Bhaumik A, Cheng S, Rooney OB, et al. Efficacy of apalutamide (APA) plus ongoing androgen deprivation therapy (ADT) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) and baseline (BL) comorbidities (CM). Journal of Clinical Oncology. 37: 5023-5023. DOI: 10.1200/Jco.2019.37.15_Suppl.5023 |
0.542 |
|
| 2019 |
Tombal BF, Loriot Y, Saad F, McDermott RS, Elliott T, Rodriguez-Vida A, Nole F, Fournier B, Collette L, Gillessen S. Decreased fracture rate by mandating bone-protecting agents in the EORTC 1333/PEACE III trial comparing enzalutamide and Ra223 versus enzalutamide alone: An interim safety analysis. Journal of Clinical Oncology. 37: 5007-5007. DOI: 10.1200/Jco.2019.37.15_Suppl.5007 |
0.432 |
|
| 2019 |
Dankner M, Ouellet V, Desreumaux-Communal L, Schmitt E, Perkins D, Annis MG, Barres V, Caron C, Mes-Masson A, Saad F, Siegel PM. Abstract 3134: CCN3 is a prognostic biomarker and functional mediator of prostate cancer bone metastasis Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-3134 |
0.524 |
|
| 2019 |
Feng F, Thomas S, Gormley M, Lopez-Gitlitz A, Yu MK, Cheng S, Ricci DS, Rooney B, Mainwaring PN, Olmos D, Saad F, Chowdhury S, Hadaschik B, Fishbane N, Davicioni E, et al. Abstract CT129: Identifying molecular determinants of response to apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) in the SPARTAN study Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct129 |
0.494 |
|
| 2019 |
Hadaschik BA, Saad F, Graff JN, Olmos D, Oudard S, Mainwaring PN, Uemura H, Lee JY, Lopez-Gitlitz A, Bhaumik A, Londhe A, Cheng S, Todd MB, Small EJ, Smith MR. Mp34-19 Efficacy And Safety Of Apalutamide (Apa) In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Patients (Pts) With Or Without Prior Radical Prostatectomy (Rp) And/Or External Radiotherapy (Xrt): Post Hoc Analysis Of Spartan The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555933.20995.42 |
0.547 |
|
| 2019 |
Graff JN, Saad F, Hadaschik BA, Mainwaring PN, Uemura H, Chowdhury S, Oudard S, Olmos D, Lee JY, Lopez-Gitlitz A, Bhaumik A, Londhe A, Cheng S, Todd MB, Smith MR, et al. Mp34-20 Metastasis-Free Survival (Mfs) In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Patients (Pts) With Prostate-Specific Antigen (Psa) Decline To < 0.2 Ng/Ml Following Apalutamide (Apa) Treatment: Post Hoc Results From The Phase 3 Spartan Study The Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555927.90500.B0 |
0.573 |
|
| 2019 |
Saad* F, Sternberg CN, Efstathiou E, Fizazi K, Modelska K, Guan X, Sugg J, Steinberg J, Noerby B. MP34-17 A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ENZALUTAMIDE IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER: POST HOC ANALYSIS OF PROSPER BY PROSTATE SPECIFIC-ANTIGEN PROGRESSION Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555909.47437.02 |
0.575 |
|
| 2019 |
Saad* F, Shore ND, Fizazi K, Steinberg J, Kim J, Lin P, Modelska K, Beer TM. PD15-07 IMPACT OF BONE-TARGETED THERAPIES IN PATIENTS WITH CHEMOTHERAPY-NAIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER ON ENZALUTAMIDE: A POST HOC ANALYSIS OF PREVAIL Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555460.30099.9F |
0.501 |
|
| 2019 |
Saad* F, Thomas S, Feng FY, Gormley M, Lopez-Gitlitz A, Yu MK, Cheng S, Ricci DS, Rooney OB, Mainwaring PN, Olmos D, Chowdhury S, Hadaschik BA, Fishbane N, Davicioni E, et al. PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE Journal of Urology. 201. DOI: 10.1097/01.Ju.0000555359.59547.3E |
0.466 |
|
| 2019 |
Fizazi K, Mella PG, Castellano D, Minatta JN, Kalebasty AR, Shaffer D, Limon JCV, Armstrong AJ, Lopez HMS, Sharkey B, Saci A, Li J, Wang X, Ciprotti M, Sathyanarayana P, ... Saad F, et al. Efficacy and safety of nivolumab in combination with docetaxel in men with metastatic castration-resistant prostate cancer in CheckMate 9KD Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.045 |
0.53 |
|
| 2019 |
Smith MR, Sandhu SK, Kelly WK, Scher HI, Efstathiou E, Lara PN, Yu EY, George DJ, Chi KN, Saad F, Summa J, Freedman JM, Mason GE, Zhu E, Ricci D, et al. Pre-specified interim analysis of GALAHAD: A phase II study of niraparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects (DRD) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.043 |
0.304 |
|
| 2019 |
Parker C, Clarke NW, Cook A, Kynaston HG, Petersen PM, Cross W, Persad R, Catton C, Logue J, Payne H, Saad F, Brasso K, Lindberg H, Zarkar A, Raman R, et al. Timing of radiotherapy (RT) after radical prostatectomy (RP): First results from the RADICALS RT randomised controlled trial (RCT) [NCT00541047] Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz394.042 |
0.306 |
|
| 2019 |
Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi K, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Mehra N, Goessl C, Kang J, et al. PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations Annals of Oncology. 30: v881-v882. DOI: 10.1093/Annonc/Mdz394.039 |
0.51 |
|
| 2019 |
Fu SYF, Murtha A, Herberts C, Yip S, Angeles A, Hotte SJ, Alshangiti A, Tran B, Taavitsainen S, Annala M, Saad F, Iqbal NN, Wyatt AW, Chi KN. Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC) Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz248.039 |
0.369 |
|
| 2019 |
de Bono J, Fizazi K, Saad F, Shore N, Sandhu S, Mehra N, Kolinsky M, Roubaud G, Özgüroǧlu M, Matsubara N, Gedye C, Choi Y, Padua C, Goessl C, Kohlmann A, et al. Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study Annals of Oncology. 30: v328-v329. DOI: 10.1093/Annonc/Mdz248.004 |
0.474 |
|
| 2019 |
Trudel D, Grosset A, Dallaire F, Nguyen T, Kougioumoutzakis A, Azzi F, Aubertin K, Saad F, Latour M, Albadine R, Boutros P, Fraser M, Bristow RG, Kwast Tvd, Benzerdjeb N, et al. Raman microscopy for the identification of an aggressive variant of prostate cancer, intraductal carcinoma of the prostate Annals of Oncology. 30. DOI: 10.1093/Annonc/Mdz239.002 |
0.483 |
|
| 2019 |
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Ye D, Mateo J, Goessl C, Kang J, Liu S, Saad F. PROPEL: A randomized phase III trial evaluating the efficacy and safety of olaparib combined with abiraterone as first-line therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)31321-1 |
0.503 |
|
| 2019 |
Feyerabend S, Saad F, Ito T, Diels J, Sanden SV, Porre PD, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K. Overall survival with abiraterone acetate plus prednisone vs. docetaxel for the treatment of metastatic hormone-sensitive prostate cancer: An updated network meta-analysis European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)31009-7 |
0.528 |
|
| 2019 |
Armstrong A, Tombal B, Saad F, Parli T, Phung D, Beer TM. Enzalutamide in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Long-term overall survival and safety analyses of the phase 3 PREVAIL study European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30874-7 |
0.523 |
|
| 2019 |
Hadaschik B, Weber M, Iravani A, Hofman MS, Calais J, Czernin J, Ilhan H, Saad F, Small EJ, Smith MR, Perez PM, Hope TA, Rauscher I, Londhe A, Lopez-Gitlitz A, et al. Prostate-specific membrane antigen positron-emission tomography (PSMA-PET) in high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC) SPARTAN-like patients (pts) negative by conventional imaging European Urology Supplements. 18. DOI: 10.1016/S1569-9056(19)30510-X |
0.459 |
|
| 2019 |
Ménard C, Delouya G, Wong P, Beauchemin M, Barkati M, Taussky D, Bahary J, Schuster T, Roberge D, DaSilva J, Juneau D, Saad F. 161 PSMA-PET Guided Intensification of Radiotherapy for Prostate Cancer: Preliminary Detection Rate and Impact on Radiotherapeutic Management Radiotherapy and Oncology. 139. DOI: 10.1016/S0167-8140(19)33217-7 |
0.494 |
|
| 2019 |
O’sullivan JM, Miller K, Heinrich D, Carles J, Wirth M, Nilsson S, Heidenreich A, Kalinovsky J, Saad F. Radium-223 (Ra-223) Therapy after Abiraterone: Analysis of Symptomatic Skeletal Events (SSEs) in an International Early Access Program (iEAP) in Patients with Metastatic castration-Resistant Prostate Cancer (mCRPC) Journal of Medical Imaging and Radiation Sciences. 50. DOI: 10.1016/J.Jmir.2019.03.122 |
0.498 |
|
| 2019 |
O’sullivan JM, Sternberg CN, Harshman L, Logue J, Baldari S, Richardson T, Bottomley D, Schostak M, Kalinovsky J, Bayh I, Higano C, Tombal B, Miller K, Saad F, Sartor O, et al. Use of Bone Health Agents (BHAs) in Patients with Metastatic Castration-resistant Prostate Cancer (mCRPC) Treated with Radium-223 after Abiraterone: An Interim Review of Reassure Journal of Medical Imaging and Radiation Sciences. 50. DOI: 10.1016/J.Jmir.2019.03.120 |
0.527 |
|
| 2018 |
Smith MR, Parker CC, Saad F, Miller K, Tombal B, Ng QS, Bögemann M, Matveev V, Piulats JM, Zucca LE, Heidenreich A, Kakehi Y, Zhang A, Krissel H, Shen J, et al. ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients (pts) with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii723. PMID 32137997 DOI: 10.1093/Annonc/Mdy424.035 |
0.524 |
|
| 2018 |
Carr TH, Adelman C, Barnicle A, Kozarewa I, Luke S, Lai Z, Menon S, Hollis S, Dougherty B, Harrington EA, Barrett JC, Goessl C, Saad F, Sala N, Clarke NW, et al. Multimodal detection of homologous recombination repair gene mutations (HRRm) in a phase II trial of olaparib plus abiraterone in metastatic castrate resistant prostate cancer (mCRPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii30. PMID 32136698 DOI: 10.1093/Annonc/Mdy269.095 |
0.474 |
|
| 2018 |
Saad F, Chi KN, Shore N, Graff JN, Posadas EM, Freeman S, Tryon J, Trudel GC, de Jong J, Meltzer J, Zhao X, Tran N, Rezazadeh A. Interim results of a phase Ib study of niraparib plus androgen receptor-targeted therapy in men with metastatic castration-resistant prostate cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii292. PMID 32136670 DOI: 10.1093/Annonc/Mdy284.043 |
0.527 |
|
| 2018 |
Miller K, Heinrich D, O'Sullivan JM, Carles J, Wirth M, Nilsson S, Huang L, Kalinovsky J, Heidenreich A, Saad F. Radium-223 (Ra-223) therapy after abiraterone (Abi): Analysis of symptomatic skeletal events (SSEs) in an international early access program (iEAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii287. PMID 32136658 DOI: 10.1093/Annonc/Mdy284.033 |
0.498 |
|
| 2018 |
Small EJ, Cella D, McQuarrie K, Saad F, Hadaschik BA, Graff JN, Uemura H, Oudard S, Yu MK, Hudgens S, Lopez-Gitlitz A, Rooney B, Morris M, Smith MR. Health-related quality of life (HRQoL) after progressive disease (PD) in SPARTAN: A phase III trial of apalutamide (APA) versus placebo (PBO) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii276-viii277. PMID 32136633 DOI: 10.1093/Annonc/Mdy284.013 |
0.456 |
|
| 2018 |
Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, Shariat SF, Saad F, Briganti A, Karakiewicz PI. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. European Urology Oncology. PMID 31411992 DOI: 10.1016/J.Euo.2018.10.010 |
0.503 |
|
| 2018 |
Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. European Urology Oncology. 1: 215-222. PMID 31102624 DOI: 10.1016/J.Euo.2018.03.007 |
0.537 |
|
| 2018 |
Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, Briganti A, Karakiewicz P. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. European Urology Oncology. 1: 314-320. PMID 31100253 DOI: 10.1016/J.Euo.2018.04.013 |
0.554 |
|
| 2018 |
Zaffuto E, Bandini M, Moschini M, Leyh-Bannurah SR, Gazdovich S, Dell'Oglio P, Gallina A, Shariat SF, Briganti A, Montorsi F, Saad F, Karakiewicz PI. Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. European Urology Oncology. 1: 169-175. PMID 31100242 DOI: 10.1016/J.Euo.2018.02.001 |
0.438 |
|
| 2018 |
Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Saad F, Pompe RS, Briganti A, Budäus L, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. European Urology Oncology. 1: 160-168. PMID 31100241 DOI: 10.1016/J.Euo.2018.03.006 |
0.551 |
|
| 2018 |
Aubertin K, Desroches J, Jermyn M, Trinh VQ, Saad F, Trudel D, Leblond F. Combining high wavenumber and fingerprint Raman spectroscopy for the detection of prostate cancer during radical prostatectomy. Biomedical Optics Express. 9: 4294-4305. PMID 30615702 DOI: 10.1364/Boe.9.004294 |
0.491 |
|
| 2018 |
Preisser F, Mazzone E, Nazzani S, Knipper S, Tian Z, Mandel P, Pompe R, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI. Impact of Age on Perioperative Outcomes at Radical Prostatectomy: A Population-Based Study. European Urology Focus. 6: 1213-1219. PMID 30594487 DOI: 10.1016/J.Euf.2018.12.006 |
0.353 |
|
| 2018 |
Delouya G, Tiberi D, Bhatnagar SR, Campeau S, Saad F, Taussky D. Impact of adipose tissue on prostate cancer aggressiveness - analysis of a high-risk population. Hormone Molecular Biology and Clinical Investigation. PMID 30471220 DOI: 10.1515/Hmbci-2018-0049 |
0.423 |
|
| 2018 |
Preisser F, Mazzone E, Nazzani S, Marchioni M, Bandini M, Tian Z, Saad F, Soulières D, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. North American population-based validation of the National Comprehensive Cancer Network Practice Guideline Recommendations for locoregional lymph node and bone imaging in prostate cancer patients. British Journal of Cancer. PMID 30425350 DOI: 10.1038/S41416-018-0323-3 |
0.481 |
|
| 2018 |
Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF, Tian Z, Saad F, Montorsi F, Zorn KC, Graefen M, Tilki D, Karakiewicz PI. Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer. Clinical Genitourinary Cancer. PMID 30366880 DOI: 10.1016/J.Clgc.2018.09.024 |
0.538 |
|
| 2018 |
Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, Suardi N, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study. Clinical Genitourinary Cancer. PMID 30342845 DOI: 10.1016/J.Clgc.2018.09.011 |
0.503 |
|
| 2018 |
Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulieres D, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, Karakiewicz P. The effect of race on survival after local therapy in metastatic prostate cancer patients. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 30332592 DOI: 10.5489/Cuaj.5399 |
0.566 |
|
| 2018 |
Parker C, Lewington V, Shore N, Kratochwil C, Levy M, Lindén O, Noordzij W, Park J, Saad F. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review. Jama Oncology. PMID 30326033 DOI: 10.1001/Jamaoncol.2018.4044 |
0.339 |
|
| 2018 |
Preisser F, Nazzani S, Mazzone E, Knipper S, Bandini M, Tian Z, Haese A, Saad F, Zorn KC, Montorsi F, Shariat SF, Graefen M, Tilki D, Karakiewicz PI. Regional differences in total hospital charges between open and robotically assisted radical prostatectomy in the United States. World Journal of Urology. PMID 30315358 DOI: 10.1007/S00345-018-2525-Y |
0.381 |
|
| 2018 |
Sharma NV, Pellegrini KL, Ouellet V, Giuste FO, Ramalingam S, Watanabe K, Adam-Granger E, Fossouo L, You S, Freeman MR, Vertino P, Conneely K, Osunkoya AO, Trudel D, Mes-Masson AM, ... ... Saad F, et al. Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. Cancers. 10. PMID 30314329 DOI: 10.3390/Cancers10100379 |
0.56 |
|
| 2018 |
Tagawa ST, Antonarakis ES, Gjyrezi A, Galletti G, Kim S, Worroll D, Stewart J, Zaher A, Szatrowski TP, Ballman KV, Kita K, Tasaki S, Bai Y, Portella L, Kirby BJ, ... Saad F, et al. Expression of AR-V7 and ARv567es in circulating tumor cells correlates with outcomes to taxane therapy in men with metastatic prostate cancer treated in TAXYNERGY. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30301829 DOI: 10.1158/1078-0432.Ccr-18-0320 |
0.519 |
|
| 2018 |
Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, Briganti A, Carmignani L, Karakiewicz PI. Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non-metastatic urothelial carcinoma of the upper urinary tract. World Journal of Urology. PMID 30298285 DOI: 10.1007/S00345-018-2516-Z |
0.328 |
|
| 2018 |
Hussain M, Saad F, Sternberg CN. Enzalutamide in Castration-Resistant Prostate Cancer. The New England Journal of Medicine. 379: 1381. PMID 30284801 DOI: 10.1056/Nejmc1810065 |
0.543 |
|
| 2018 |
Hussain M, Saad F, Sternberg CN. Enzalutamide in Castration-Resistant Prostate Cancer. The New England Journal of Medicine. 379: 1381. PMID 30281993 DOI: 10.1056/NEJMc1810065#SA3 |
0.471 |
|
| 2018 |
Taussky D, Preisser F, Karakiewicz PI, Tilki D, Lambert C, Bahary JP, Delouya G, Wistaff R, Laskine M, Nguyen PV, Durand M, Saad F. Impact of diabetes and metformin use on prostate cancer outcome of patients treated with radiation therapy: results from a large institutional database. The Canadian Journal of Urology. 25: 9509-9515. PMID 30281009 |
0.486 |
|
| 2018 |
Saad F, Pouliot F, Danielson B, Catton C, Kapoor A. Symptom assessment to guide treatment selection and determine progression in metastatic castration-resistant prostate cancer: Expert opinion and review of the evidence. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 12: E415-E420. PMID 30227914 DOI: 10.5489/Cuaj.5154 |
0.438 |
|
| 2018 |
Feyerabend S, Saad F, Li T, Ito T, Diels J, Van Sanden S, De Porre P, Roiz J, Abogunrin S, Koufopoulou M, Fizazi K. Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysis. European Journal of Cancer (Oxford, England : 1990). 103: 78-87. PMID 30218976 DOI: 10.1016/J.Ejca.2018.08.010 |
0.562 |
|
| 2018 |
Saad F, Cella D, Basch E, Hadaschik BA, Mainwaring PN, Oudard S, Graff JN, McQuarrie K, Li S, Hudgens S, Lawson J, Lopez-Gitlitz A, Yu MK, Smith MR, Small EJ. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, phase 3 trial. The Lancet. Oncology. PMID 30213449 DOI: 10.1016/S1470-2045(18)30456-X |
0.525 |
|
| 2018 |
Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Lacombe L, Lattouf JB, van der Kwast T, ... ... Saad F, et al. The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation. Bmc Urology. 18: 78. PMID 30200929 DOI: 10.1186/S12894-018-0392-X |
0.534 |
|
| 2018 |
Mazzone E, Nazzani S, Preisser F, Tian Z, Marchioni M, Bandini M, Capitanio U, Kapoor A, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, I Karakiewicz P. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. Cancer Epidemiology. 56: 118-125. PMID 30173050 DOI: 10.1016/J.Canep.2018.08.006 |
0.34 |
|
| 2018 |
Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Saad F, Chun FK, Shariat SF, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Racial disparities in lymph node dissection at radical prostatectomy: A Surveillance, Epidemiology and End Results database analysis. International Journal of Urology : Official Journal of the Japanese Urological Association. PMID 30146729 DOI: 10.1111/Iju.13780 |
0.34 |
|
| 2018 |
Saad F. What is urology Cuaj-Canadian Urological Association Journal. 12: 225. PMID 30138087 DOI: 10.5489/Cuaj.5536 |
0.372 |
|
| 2018 |
Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, O'Flaherty A, Scarlata E, Saad F, Carmel M, Lacombe L, Brimo F, Latour M, Ekindi-Ndongo N, Têtu B, Aprikian A. The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer. World Journal of Urology. PMID 30136199 DOI: 10.1007/S00345-018-2457-6 |
0.47 |
|
| 2018 |
Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Ekindi-Ndongo N, Latour M, Trudel D, et al. Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer. Bju International. PMID 30113732 DOI: 10.1111/Bju.14512 |
0.526 |
|
| 2018 |
Saad F. Improving outcome in patients with prostate and kidney cancer: heading in the right direction? Current Opinion in Supportive and Palliative Care. 12: 323-324. PMID 30074925 DOI: 10.1097/Spc.0000000000000368 |
0.514 |
|
| 2018 |
Sathianathen NJ, Konety BR, Crook J, Saad F, Lawrentschuk NL. Landmarks in prostate cancer. Nature Reviews Urology. 15: 627-642. PMID 30065357 DOI: 10.1038/S41585-018-0060-7 |
0.518 |
|
| 2018 |
Preisser F, Mazzone E, Nazzani S, Bandini M, Tian Z, Marchioni M, Steuber T, Saad F, Montorsi F, Shariat SF, Huland H, Graefen M, Tilki D, Karakiewicz PI. Comparison of Perioperative Outcomes Between Cytoreductive Radical Prostatectomy and Radical Prostatectomy for Nonmetastatic Prostate Cancer. European Urology. PMID 30037529 DOI: 10.1016/J.Eururo.2018.07.006 |
0.446 |
|
| 2018 |
Hamilou Z, Saad F, Fizazi K. Treatment of hormone-naïve metastatic prostate cancer. Current Opinion in Supportive and Palliative Care. 12: 334-338. PMID 30015691 DOI: 10.1097/Spc.0000000000000359 |
0.573 |
|
| 2018 |
Traboulsi SL, Saad F. Management of nonmetastatic castration-resistant prostate cancer. Current Opinion in Supportive and Palliative Care. 12: 366-371. PMID 30015690 DOI: 10.1097/Spc.0000000000000356 |
0.589 |
|
| 2018 |
Belderbos BPSI, de Wit R, Chien C, Mitselos A, Hellemans P, Jiao J, Yu MK, Attard G, Bulat I, Edenfield WJ, Saad F. An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. Cancer Chemotherapy and Pharmacology. PMID 29974203 DOI: 10.1007/S00280-018-3632-6 |
0.526 |
|
| 2018 |
Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. Clinical Genitourinary Cancer. PMID 29954690 DOI: 10.1016/J.Clgc.2018.05.016 |
0.541 |
|
| 2018 |
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung, Krivoshik A, Sternberg CN. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. The New England Journal of Medicine. 378: 2465-2474. PMID 29949494 DOI: 10.1056/Nejmoa1800536 |
0.586 |
|
| 2018 |
Saad F, Fleshner NE, So A, Le Lorier J, Perrault L, Poulin-Costello M, Rogoza R, Robson EJD. The burden of symptomatic skeletal events in castrate-resistant prostate cancer patients with bone metastases at three Canadian uro-oncology centres. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29940132 DOI: 10.5489/Cuaj.5053 |
0.522 |
|
| 2018 |
Atherton MJ, Stephenson KB, Tzelepis F, Bakhshinyan D, Nikota JK, Son HH, Jirovec A, Lefebvre C, Dvorkin-Gheva A, Ashkar AA, Wan Y, Stojdl DF, Belanger EC, Breau RH, Bell JC, ... Saad F, et al. Transforming the prostatic tumor microenvironment with oncolytic virotherapy. Oncoimmunology. 7: e1445459. PMID 29900060 DOI: 10.1080/2162402X.2018.1445459 |
0.451 |
|
| 2018 |
Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Montorsi F, Saad F, Briganti A, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI. Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. Urologic Oncology. PMID 29887241 DOI: 10.1016/J.Urolonc.2018.05.019 |
0.43 |
|
| 2018 |
Pang K, Fitch M, Ouellet V, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, So A, Sutcliffe S, Tanguay S, Saad F, Mes-Masson AM. Describing perspectives of health care professionals on active surveillance for the management of prostate cancer. Bmc Health Services Research. 18: 430. PMID 29884180 DOI: 10.1186/S12913-018-3273-9 |
0.461 |
|
| 2018 |
Clarke N, Wiechno P, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Fléchon A, Redfern C, Goessl C, Burgents J, Kozarski R, Hodgson D, Learoyd M, ... Saad F, et al. Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet. Oncology. PMID 29880291 DOI: 10.1016/S1470-2045(18)30365-6 |
0.538 |
|
| 2018 |
Preisser F, Bandini M, Mazzone E, Nazzani S, Marchioni M, Tian Z, Saad F, Pompe RS, Shariat SF, Heinzer H, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results database. European Urology Focus. PMID 29802052 DOI: 10.1016/J.Euf.2018.05.006 |
0.509 |
|
| 2018 |
Saad F. Reliably Quantifying Bone Metastases in Prostate Cancer-Are We Finally There? Jama Oncology. 4: 951-952. PMID 29799991 DOI: 10.1001/Jamaoncol.2018.1069 |
0.532 |
|
| 2018 |
Saad F, Sternberg CN, Mulders PFA, Niepel D, Tombal BF. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer. Cancer Treatment Reviews. 68: 25-37. PMID 29787892 DOI: 10.1016/J.Ctrv.2018.04.014 |
0.547 |
|
| 2018 |
Newton RU, Kenfield SA, Hart NH, Chan JM, Courneya KS, Catto J, Finn SP, Greenwood R, Hughes DC, Mucci L, Plymate SR, Praet SFE, Guinan EM, Van Blarigan EL, Casey O, ... ... Saad F, et al. Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. Bmj Open. 8: e022899. PMID 29764892 DOI: 10.1136/Bmjopen-2018-022899 |
0.536 |
|
| 2018 |
Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, Shariat SF, Saad F, Briganti A, Karakiewicz PI. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. World Journal of Urology. PMID 29717358 DOI: 10.1007/S00345-018-2310-Y |
0.553 |
|
| 2018 |
Woon DTS, Chandrasekar T, Aaron L, Basappa NS, Chi KN, Conter HJ, Danielson B, Hotte SJ, Malone S, Saad F, Shayegan B, Park-Wyllie L, Hamilton RJ. Disparity in public funding of therapies for metastatic castrate-resistant prostate cancer across Canadian provinces. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29688882 DOI: 10.5489/Cuaj.5378 |
0.553 |
|
| 2018 |
Klotz L, Shayegan B, Guillemette C, Collins LL, Gotto G, Guérette D, Jammal MP, Pickles T, Richard PO, Saad F. Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 12: 30-37. PMID 29680011 DOI: 10.5489/Cuaj.5116 |
0.497 |
|
| 2018 |
Yokom DW, Stewart J, Alimohamed NS, Winquist E, Berry S, Hubay S, Lattouf JB, Leonard H, Girolametto C, Saad F, Sridhar SS. Prognostic and predictive clinical factors in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29629866 DOI: 10.5489/Cuaj.5108 |
0.522 |
|
| 2018 |
Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Mes-Masson AM, Saad F, et al. A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores. Pathology Oncology Research : Por. PMID 29623528 DOI: 10.1007/S12253-018-0408-6 |
0.429 |
|
| 2018 |
Kassouf W, Aprikian A, Saad F, Breau RH, Kulkarni G, Guttman DM, Bagshaw K, Izawa J, Eapen L, Fairey A, So A, North S, Rendon R, Sridhar SS, Brimo F, et al. Improving patient journey and quality of care: Summary from the 2nd Bladder Cancer Canada-Canadian Urological Association-Canadian Urologic Oncology Group (BCC-CUA-CUOG) bladder cancer quality of care consensus meeting. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. PMID 29603921 DOI: 10.5489/Cuaj.5246 |
0.347 |
|
| 2018 |
Trinh VQ, Sirois J, Benzerdjeb N, Mansoori BK, Grosset AA, Albadine R, Latour M, Mes-Masson AM, Hovington H, Bergeron A, Ladouceur M, Fradet Y, Saad F, Trudel D. The impact of intraductal carcinoma of the prostate on the site and timing of recurrence and cancer-specific survival. The Prostate. PMID 29603326 DOI: 10.1002/Pros.23513 |
0.545 |
|
| 2018 |
Aubertin K, Trinh VQ, Jermyn M, Baksic P, Grosset AA, Desroches J, St-Arnaud K, Birlea M, Vladoiu MC, Latour M, Albadine R, Saad F, Leblond F, Trudel D. Mesoscopic characterization of prostate cancer using Raman spectroscopy: Potential for diagnostics and therapeutics. Bju International. PMID 29542855 DOI: 10.1111/Bju.14199 |
0.526 |
|
| 2018 |
Klotz L, Loblaw A, Siemens R, Ouellette P, Kapoor A, Kebabdjian M, Zhang L, Saad F. A phase II, randomized, multicentre study comparing 10 months versus 4 months of degarelix (Firmagon®) therapy in prolonging the off treatment interval in men with localized prostate cancer receiving intermittent androgen deprivation therapy for biochemical recurrence following radical local therapy. The Journal of Urology. PMID 29534997 DOI: 10.1016/J.Juro.2018.03.010 |
0.465 |
|
| 2018 |
Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, Briganti A, Saad F, Shariat SF, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node invasion. The Prostate. PMID 29460290 DOI: 10.1002/Pros.23491 |
0.432 |
|
| 2018 |
Dell'Oglio P, Bandini M, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, Fossati N, Moschini M, Gandaglia G, Capitanio U, Briganti A, Graefen M, Montorsi F, Saad F, Karakiewicz PI. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. Urologic Oncology. PMID 29426698 DOI: 10.1016/J.Urolonc.2018.01.004 |
0.554 |
|
| 2018 |
Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. The New England Journal of Medicine. PMID 29420164 DOI: 10.1056/Nejmoa1715546 |
0.564 |
|
| 2018 |
Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, Abdollah F, Shariat SF, Montorsi F, Saad F, Tilki D, Briganti A, Karakiewicz PI. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. European Urology Focus. PMID 29366856 DOI: 10.1016/J.Euf.2018.01.009 |
0.514 |
|
| 2018 |
Pompe RS, Smith A, Bandini M, Marchioni M, Martel T, Preisser F, Leyh-Bannurah SR, Schiffmann J, Saad F, Huland H, Graefen M, Shariat SF, Tilki D, Karakiewicz PI. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study. Prostate Cancer and Prostatic Diseases. PMID 29339806 DOI: 10.1038/S41391-017-0006-9 |
0.506 |
|
| 2018 |
Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Pompe RS, Montorsi F, Saad F, Abdollah F, Steuber T, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI. The Impact of Lymph Node Metastases Burden at Radical Prostatectomy. European Urology Focus. PMID 29306731 DOI: 10.1016/J.Euf.2017.12.009 |
0.442 |
|
| 2018 |
Saad F. The evolving role of chemotherapy in prostate cancer. Current Opinion in Supportive and Palliative Care. 10: 262-5. PMID 27489183 DOI: 10.1097/SPC.0000000000000216 |
0.514 |
|
| 2018 |
Saad F. Canadian urology: Putting the patient first Cuaj-Canadian Urological Association Journal. 12. DOI: 10.5489/Cuaj.5765 |
0.307 |
|
| 2018 |
Klotz L, Shayegan B, Guillemette C, Collins LL, Gotto G, Guérette D, Jammal M, Pickles T, Richard PO, Saad F. Supplementary data: Testosterone suppression in the treatment of recurrent or metastatic prostate cancer – A Canadian consensus statement Canadian Urological Association Journal. 12: E45-6. DOI: 10.5489/Cuaj.5206 |
0.533 |
|
| 2018 |
Tombal BF, Gillessen S, Loriot Y, Marreaud S, Collette L, Saad F. Intergroup study EORTC-1532-gucg: A phase 2 randomized open-label study of oral darolutamide (ODM-201) vs. androgen deprivation therapy (ADT) with LHRH agonists or antagonist in men with hormone naive prostate cancer (PCa). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps406 |
0.454 |
|
| 2018 |
Tombal BF, Loriot Y, Saad F, McDermott RS, Marreaud S, Collette L, Gillessen S. Intergroup study EORTC-1333-GUCG: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer (CRPC) patients metastatic to bone (PEACE III). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps390 |
0.417 |
|
| 2018 |
Smith MR, Saad F, Hussain M, Sternberg CN, Fizazi K, Yamada KS, Kappeler C, Kuss I, Tombal BF. ARASENS: A phase 3 trial of darolutamide in combination with docetaxel for men with metastatic hormone-sensitive prostate cancer (mHSPC). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.6_Suppl.Tps383 |
0.51 |
|
| 2018 |
Saad F, Fitch M, Pang K, Ouellet V, Loiselle C, Chevalier S, Drachenberg D, Finelli A, Sutcliffe S, So AI, Tanguay S, Mes-Masson A. Perspectives of prostate cancer patients about active surveillance. Journal of Clinical Oncology. 36: 82-82. DOI: 10.1200/Jco.2018.36.6_Suppl.82 |
0.422 |
|
| 2018 |
Saad F, Pang K, Fitch M, Ouellet V, Chevalier S, Drachenberg D, Finelli A, Lattouf J, So A, Sutcliffe S, Tanguay S, Mes-Masson A. Perspectives of health care professionals on active surveillance for the management of prostate cancer. Journal of Clinical Oncology. 36: 81-81. DOI: 10.1200/Jco.2018.36.6_Suppl.81 |
0.448 |
|
| 2018 |
Saad F, Ouellet V, Grosset A, Caron C, Barres V, Latour M, Trudel D, Aprikian AG, Bergeron A, Brimo F, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, et al. Nuclear factor-kappa B p65 evaluation on the Canadian Prostate Cancer Biomarker Network (CPCBN) TMA-series for biomarker validation. Journal of Clinical Oncology. 36: 80-80. DOI: 10.1200/Jco.2018.36.6_Suppl.80 |
0.442 |
|
| 2018 |
Shayegan B, So AI, Malone S, Hotte SJ, Finelli A, Canil CM, Hew H, Park-Wyllie L, Chi KN, Saad F. Patterns of prostate cancer management across Canadian prostate cancer treatment specialists. Journal of Clinical Oncology. 36: 321-321. DOI: 10.1200/Jco.2018.36.6_Suppl.321 |
0.515 |
|
| 2018 |
Hotte SJ, Finelli A, Malone S, Shayegan B, So AI, Canil CM, Hew H, Park-Wyllie L, Saad F, Chi KN. Real world patterns of treatment sequencing in Canada for metastatic castrate-resistant prostate cancer. Journal of Clinical Oncology. 36: 320-320. DOI: 10.1200/Jco.2018.36.6_Suppl.320 |
0.523 |
|
| 2018 |
Hussain M, Fizazi K, Saad F, Rathenborg P, Shore ND, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) Journal of Clinical Oncology. 36: 3-3. DOI: 10.1200/Jco.2018.36.6_Suppl.3 |
0.474 |
|
| 2018 |
Clairefond S, Péant B, Ouellet V, Barres V, Mes-Masson A, Saad F. Evaluation of PUMA and NOXA expression as predictive biomarkers in prostate cancer. Journal of Clinical Oncology. 36: 28-28. DOI: 10.1200/Jco.2018.36.6_Suppl.28 |
0.456 |
|
| 2018 |
Feyerabend S, Saad F, Li T, Ito T, Diels J, Sanden SV, Porre PD, Abogunrin S, Koufopoulou M, Fizazi K. Indirect treatment comparison (ITC) of abiraterone acetate (AA) plus prednisone (P) and docetaxel (DOC) on patient-reported outcomes (PROs) in metastatic castration-naïve prostate cancer (mCNPC). Journal of Clinical Oncology. 36: 200-200. DOI: 10.1200/Jco.2018.36.6_Suppl.200 |
0.479 |
|
| 2018 |
Beer TM, Chowdhury S, Saad F, Shore ND, Higano CS, Iversen P, Fizazi K, Miller K, Heidenreich A, Kim CS, Phung D, Barrus JK, Nikolayeva N, Krivoshik A, Waksman J, et al. Hepatic effects assessed by review of safety data in enzalutamide castration-resistant prostate cancer (CRPC) trials. Journal of Clinical Oncology. 36: 199-199. DOI: 10.1200/Jco.2018.36.6_Suppl.199 |
0.365 |
|
| 2018 |
Small EJ, Saad F, Chowdhury S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, Shu Y, Park YC, Rackoff WR, Yu MK, et al. SPARTAN, a phase 3 double-blind, randomized study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology. 36: 161-161. DOI: 10.1200/Jco.2018.36.6_Suppl.161 |
0.508 |
|
| 2018 |
Fizazi K, Drake CG, Shaffer DR, Pachynski R, Saad F, Ciprotti M, Kong G, Ryan CJ, Petrylak DP. An open-label, phase 2 study of nivolumab in combination with either rucaparib, docetaxel, or enzalutamide in men with castration-resistant metastatic prostate cancer (mCRPC; CheckMate 9KD). Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps3126 |
0.406 |
|
| 2018 |
Small EJ, Saad F, Zheng Y, Pan F, Mehra M, Lawson J, Hadaschik BA, Uemura H, Lee JY, Mainwaring PN, Smith MR. Impact of intervening in high-risk nonmetastatic castration-resistant prostate cancer (HRnmCRPC) on metastatic castration-resistant prostate cancer (mCRPC) disease burden. Journal of Clinical Oncology. 36. DOI: 10.1200/Jco.2018.36.15_Suppl.E17010 |
0.571 |
|
| 2018 |
Attard G, Saad F, Tombal BF, Hussain M, Sternberg CN, Phung D, Naidoo S, Modelska K, Reisman A, Ivanescu C, Penson DF. Association between health-related quality of life (HRQoL) and clinical outcomes in non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study. Journal of Clinical Oncology. 36: 5043-5043. DOI: 10.1200/Jco.2018.36.15_Suppl.5043 |
0.504 |
|
| 2018 |
Small EJ, Saad F, Rathkopf DE, Hadaschik BA, Chowdhury S, Yu MK, Lopez-Gitlitz A, Rooney OB, Shu Y, Darif M, Smith MR. Predicting disease progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): An analysis from the phase 3 SPARTAN trial. Journal of Clinical Oncology. 36: 5034-5034. DOI: 10.1200/Jco.2018.36.15_Suppl.5034 |
0.553 |
|
| 2018 |
Smith MR, Saad F, Rathkopf DE, Hadaschik BA, Chowdhury S, Yu MK, Lopez-Gitlitz A, Rooney OB, Darif M, Small EJ. Relationship of time to metastasis (TTM) and site of metastases in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Results from the phase 3 SPARTAN trial. Journal of Clinical Oncology. 36: 5033-5033. DOI: 10.1200/Jco.2018.36.15_Suppl.5033 |
0.501 |
|
| 2018 |
Attard G, Saad F, Tombal BF, Hussain M, Sternberg CN, Phung D, Naidoo S, Modelska K, Reisman A, Ivanescu C, Penson DF. Health-related quality of life (HRQoL) deterioration and pain progression in men with non-metastatic castration-resistant prostate cancer (M0 CRPC): Results from the PROSPER study. Journal of Clinical Oncology. 36: 5010-5010. DOI: 10.1200/Jco.2018.36.15_Suppl.5010 |
0.395 |
|
| 2018 |
Sternberg CN, Saad F, Graff JN, Peer A, Vaishampayan UN, Leung E, Rosenbaum E, Gurney H, Epstein R, Davis ID, Wu B, Trandafir L, Wagner VJ, Hussain M. A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 36: 5008-5008. DOI: 10.1200/Jco.2018.36.15_Suppl.5008 |
0.447 |
|
| 2018 |
Clarke N, Wiechno PJ, Alekseev B, Sala N, Jones R, Kocak I, Chiuri VE, Jassem J, Flechon A, Redfern C, Goessl CD, Burgents J, Kozarski R, Hodgson DR, Saad F. Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial. Journal of Clinical Oncology. 36: 5003-5003. DOI: 10.1200/Jco.2018.36.15_Suppl.5003 |
0.461 |
|
| 2018 |
Simeone K, Guay-Lord R, Lateef MA, Péant B, Carmona E, Kendall-Dupont J, Orimoto AM, Gervais T, Mes-Masson A, Saad F. Novel ex vivo patient-derived 3D model as a powerful tool to apply precision medicine. Journal of Clinical Oncology. 36: 12086-12086. DOI: 10.1200/Jco.2018.36.15_Suppl.12086 |
0.489 |
|
| 2018 |
Bono JSd, Higano C, Saad F, Miller K, Casey M, Czibere A, Healy C, Fizazi K. TALAPRO-1: An open-label, response rate phase II study of talazoparib (TALA) in men with DNA damage repair defects (DDR) and metastatic castration-resistant prostate cancer (mCRPC) who previously received taxane-based chemotherapy (CT) and progressed on≥1 novel hormonal therapy (NHT). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.068 |
0.475 |
|
| 2018 |
Higano CS, Tombal B, Miller K, Saad F, Sartor O, Tangirala K, Jiao X, Kalinovsky J, Sternberg CN. Clinical outcome with radium-223 (Ra-223) in patients (pts) previously treated with abiraterone (Abi) or enzalutamide (Enza): A retrospective study of real-world (RW) data from pts with metastatic castration-resistant prostate cancer (mCRPC). Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.036 |
0.487 |
|
| 2018 |
Sternberg CN, Tombal B, Miller K, Saad F, Sartor O, Sade JP, Logothetis C, Bellmunt J, Dizdarevic S, Harshman LC, Logue J, Baldari S, Richardson T, Bottomley D, Schostak M, et al. Use of bone health agents (BHAs) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) after abiraterone (Abi): An interim review of REASSURE. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.035 |
0.501 |
|
| 2018 |
Tombal B, Hussain M, Penson D, Attard G, Sternberg CN, Phung D, Morlock R, Modelska K, Ramaswamy K, Ivanescu C, Saad F. Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.016 |
0.523 |
|
| 2018 |
Fizazi K, Hussain M, Saad F, Shore N, Giorgi UD, Efstathiou E, Ferreira U, Ivashchenko P, Madziarska K, Al-Adhami M, Modelska K, Phung D, Steinberg J, Sternberg CN. A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region. Annals of Oncology. 29. DOI: 10.1093/Annonc/Mdy284.014 |
0.492 |
|
| 2018 |
Bandini M, Suardi N, Moschini M, Smith A, Bondarenko H, Nazzani S, Marchioni M, Preisser F, Tian Z, Abdollah F, Schips L, Montorsi F, Shariat S, Saad F, Briganti A, et al. Increasing trend of non-interventional treatment management in patients candidate to active surveillance with localized prostate cancer European Urology Supplements. 17. DOI: 10.1016/S1569-9056(18)32305-4 |
0.501 |
|
| 2018 |
Preisser F, Marchioni M, Bandini M, Saad F, Graefen M, Tilki D, Karakiewicz PI. Burden of lymph node metastases in patients with prostate cancer treated with radical prostatectomy and lymph node dissection European Urology Supplements. 17. DOI: 10.1016/S1569-9056(18)32259-0 |
0.401 |
|
| 2018 |
Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Smith A, Bondarenko H, Gallina A, Abdollah F, Shariat S, Montorsi F, Saad F, Tilki D, Briganti A, Karakiewicz P. Contemporary trends and survival outcomes after aborted radical prostatectomy in lymph node metastatic prostate cancer patients European Urology Supplements. 17. DOI: 10.1016/S1569-9056(18)31657-9 |
0.503 |
|
| 2018 |
Tombal B, Hussain M, Penson D, Attard G, Sternberg CN, Phung D, Naidoo S, Modelska K, Demirhan E, Ramaswamy K, Ivanescu C, Saad F. Patient-reported outcome measures in men with non-metastatic castration-resistant prostate cancer: Baseline data from the PROSPER trial European Urology Supplements. 17. DOI: 10.1016/S1569-9056(18)31440-4 |
0.543 |
|
| 2018 |
Sternberg CN, Fizazi K, Saad F, Rathenborg P, Shore N, Demirhan E, Modelska K, Phung D, Krivoshik A, Hussain M. Prostate-specific antigen (PSA) response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) treated with enzalutamide (ENZA): Results from PROSPER European Urology Supplements. 17. DOI: 10.1016/S1569-9056(18)31439-8 |
0.54 |
|
| 2018 |
Small EJ, Lee JY, Lopez-Gitlitz A, Saad F, Rooney B, Hadaschik BA, Uemura H, Shu Y, Yu M, Smith MR. Pd10-11 Prostate-Specific Antigen (Psa) Outcomes In Patients (Pts) With Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Treated With Apalutamide (Apa): Results From Phase 3 Spartan Study The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.621 |
0.536 |
|
| 2018 |
Shore N, Saad F, Hussain M, Fizazi K, Rathenborg P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN. Pd10-09 The Prosper Trial: Chemotherapy-Related Endpoints In Patients With Nonmetastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.619 |
0.507 |
|
| 2018 |
Saad F, Mehra M, Small EJ, Lawson J, Dasgupta A, Hadaschik BA, Uemura H, Smith MR. Pd10-04 A Population-Based Study Of The Association Of Prostate-Specific Antigen Doubling Time (Psadt) With Metastasis-Free Survival (Mfs) And Overall Survival (Os) In Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Patients (Pts) The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.614 |
0.539 |
|
| 2018 |
Bandini M, Suardi N, Moschini M, Smith A, Bondarenko H, Nazani S, Marchioni M, Preisser F, Tian Z, Abdollah F, Graefen M, Montorsi F, Shariat S, Saad F, Briganti A, et al. Mp17-07 Increasing Rate Of Non-Interventional Treatment Management In Localized Prostate Cancer Candidates For Active Surveillance The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.562 |
0.476 |
|
| 2018 |
Brownfield C, Sharma N, Pellegrini K, Ouellet V, Feeman M, Osunkoya A, Saad F, Moreno C, Petros J. Pd65-02 Identification Of Coordinated Transcription Factor Groups Associated With Androgen Deprivation Therapy Response And Metastatic Progression In Prostate Cancer The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.2986 |
0.475 |
|
| 2018 |
Ory J, Breau R, Saad F, Kassouf W, Shayegan B, Duplisea J, Lawen T, Morash C, Aprikian A, Rendon RA. Pd42-05 Outcomes Of Surgical Management Of Localized High-Risk Prostate Cancer: Results From The Prostate Cancer Canadian Collaboration The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1958 |
0.519 |
|
| 2018 |
Small EJ, Saad F, Hadaschik BA, Graff JN, Mainwaring PN, McQuarrie K, Li S, Lawson J, Lopez-Gitlitz A, Smith MR. Mp52-20 Patient Reported Outcomes (Pros) In Spartan, A Phase 3, Double-Blind, Randomized Study Of Apalutamide (Apa) Plus Androgen Deprivation Therapy (Adt) Vs Placebo Plus Adt In Men With Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) The Journal of Urology. 17. DOI: 10.1016/J.Juro.2018.02.1671 |
0.551 |
|
| 2018 |
Saad F, Penson D, Attard G, Hussain M, Sternberg C, Naidoo S, Modelska K, Demirhan E, Ramaswamy K, Skaltsa K, Tombal B. Mp52-19 Impact Of Enzalutamide On Pain And Health-Related Quality Of Life In Men With Non-Metastatic Castration-Resistant Prostate Cancer: Prosper Study Results The Journal of Urology. 199. DOI: 10.1016/J.Juro.2018.02.1670 |
0.47 |
|
| 2017 |
Rendon RA, Mason RJ, Marzouk K, Finelli A, Saad F, So A, Violette P, Breau RH. Recommandations de l'Association des urologues du Canada sur le dépistage et le diagnostic précoce du cancer de la prostate. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 11: 298-309. PMID 29381452 DOI: 10.5489/Cuaj.4888 |
0.388 |
|
| 2017 |
Heller G, McCormack R, Kheoh T, Molina A, Smith MR, Dreicer R, Saad F, de Wit R, Aftab DT, Hirmand M, Limon A, Fizazi K, Fleisher M, de Bono JS, Scher HI. Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017752998. PMID 29272162 DOI: 10.1200/Jco.2017.75.2998 |
0.523 |
|
| 2017 |
Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, Briganti A, Saad F, Karakiewicz PI. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. International Urology and Nephrology. PMID 29129028 DOI: 10.1007/S11255-017-1744-2 |
0.535 |
|
| 2017 |
Fitch M, Pang K, Ouellet V, Loiselle C, Alibhai S, Chevalier S, Drachenberg DE, Finelli A, Lattouf JB, Sutcliffe S, So A, Tanguay S, Saad F, Mes-Masson AM. Canadian Men's perspectives about active surveillance in prostate cancer: need for guidance and resources. Bmc Urology. 17: 98. PMID 29078772 DOI: 10.1186/S12894-017-0290-7 |
0.519 |
|
| 2017 |
Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, Shariat SF, Briganti A, Saad F, Karakiewicz PI. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. World Journal of Urology. PMID 29063268 DOI: 10.1007/S00345-017-2102-9 |
0.526 |
|
| 2017 |
Beer TM, Hotte SJ, Saad F, Alekseev B, Matveev V, Fléchon A, Gravis G, Joly F, Chi KN, Malik Z, Blumenstein B, Stewart PS, Jacobs CA, Fizazi K. Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, phase 3 trial. The Lancet. Oncology. PMID 29033099 DOI: 10.1016/S1470-2045(17)30605-8 |
0.57 |
|
| Show low-probability matches. |